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Abstract
Thrombophilia describes the familial or acquired disorders of the haemostatic
mechanism that are likely to predispose to thrombosis. Venous thrombosis and its
associated complications account for a significant number of hospital admissions and
deaths annually having a significant health-economic impact on the heath-care
industry globally. Mutations in genes that code for proteins involved directly (or
indirectly) in blood coagulation have been associated with prothrombotic states. The
majority of inherited genetic defects were attributed to polymorphisms in
Antithrombin III, Protein C, and Protein S genes until 1994. Together these
accounted for only 5-10% of individuals with thrombosis. Subsequently the Factor V
Leiden allele (that results in activated protein C resistance) and the Prothrombin
G20210A allele (that leads to increased levels of prothrombin in blood) have been
shown to be prevalent in 45% and 18% of patients, respectively, with a history of
venous thrombosis. More recently, a G->T transversion in the blood coagulation
Factor XIII A-subunit (FXIII VaI34Leu), that interferes with fibrin cross-linking, and
a C^T transition in the Methylenetetrahydrofolate Reductase gene (MTHFR C677T)
have been implicated as risk factors for thrombosis. The potential for thrombosis is
greatly enhanced in individuals with acquired risk factors such as increased age,
malignancy, prolonged immobility and surgical trauma.

A Test group comprised of 68 subjects suspected with cancer and a randomised ageand sex-matched Control group of 68 subjects (attending the same hospital) with no
history of thrombotic or cancer-related disease were assessed in this study.
Polymerase chain reaction (PCR), site-directed mutagenesis (SDM)-PCR, and
Restriction Fragment Length Polymorphism (RFLP) analysis were used to determine
Factor V Leiden, Protein C, Antithrombin III, and MTHFR C677T genotypes. Single
Stranded Conformational Polymorphism (SSCP) analysis and DNA sequencing
detected and confirmed the presence of the Factor XIII VaI34Leu allele. Genotypes
for subjects in the Test group were compared with the ‘real-time’ coagulation
characteristics of their respective blood samples as determined using
Thromboelastography (TEG).

XI

Objectives

Screen a sample group of patients for mutations in genes that code for proteins
involved directly or indirectly with blood coagulation that are reported to be
associated with an increased risk of thrombosis.

Develop and optimise laboratory protocols for several molecular diagnostic
techniques including Polymerase Chain Reaction (PCR), Site Directed
Mutagenesis (SDM)-PCR, Restriction Fragment Length Polymorphism
(RFLP) analysis and Single Stranded Conformational Polymorphism (SSCP)
analysis.

Assess the coagulation status of subjects at the phenotypic level using
Thromboelastography (TEG).
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Section 1

Introduction

1.1

Blood Coagulation
Blood is normally maintained in a fluid state within the intact circulation by
means of complex interactions between the coagulation system, platelets,
natural inhibitors of coagulation, the fibrinolytic system and blood vessel
endothelial cells. Following vascular injury platelets are activated upon
exposure to subendothelial constituents (such as tissue thromboplastin and
collagen) and adhere to the site of injury. Subsequently, platelets undergo
physiological changes leading to a ‘release reaction’ that induces platelet
aggregation. A platelet plug is formed that reduces or temporarily stops the
loss of blood. This sets the stage for a series of proteolytic events arranged in
a cascade fashion that lead to the explosive, but yet controlled formation of
thrombin (Davie et al., 1991; Hillarp et al., 1996).

On a conceptual basis, the coagulation system (or cascade) is divided into an
intrinsic and extrinsic pathway (see Figure 1.1). All of the protein components
are present in the blood for initiation of coagulation by the intrinsic pathway.
The cell membrane protein Tissue Factor plays a critical role in the initiation
of coagulation by the extrinsic pathway. Both pathways consist of a series of
proteolytic reactions whereby proenzymes (known as factors e.g. Factor V
[FV]) are converted into their activated enzyme forms (activated factors e.g.
FVa) (Furie and Furie, 1988; Davie, 1995). The ultimate aim of the
coagulation cascade is the formation of an insoluble fibrin clot at the site of
injury. Once a stable clot has formed, wound healing ensues and the clot is
gradually dissolved by enzymes of the fibrinolytic system.

Intrinsic process

Extrinsic process

Kallikrein
HMW-kininogen

Insoluble fibrin

^ ^•

The Coagulation Cascade; Roman Numerals = blood
coagulation factors, suffix ‘a’ = ‘activated’ blood coagulation
factor; HMW = High Molecular Weight, Factor VIIIC =
Factor VIII cofactor.

Mechanisms exist to maintain a balance between the potential for
inappropriate thrombosis and inappropriate haemorrhage. The principle
natural anticoagulant systems that exert damping effects on the various steps
of the cascade are the heparin-antithrombin III (ATIII) mechanism that
regulates the serine proteases (i.e. Factors Ila, Vila, IXa, Xa, XIa, Xlla) and
the Protein C-thrombomodulin mechanism that regulates the activated
cofactors (i.e. Factors Va and Villa) (Dahlback, 1994). ATIII is a member of
a group of circulating plasma ^ine protease inhibitors (SERFINS) that also
includes heparin cofactor II, plasminogen activator inhibitor (PAI-1),
a2-plasmin inhibitor (a2PI) and a2-macroglobulin. Other regulating
mechanisms employed to prevent undesired clot formation include good blood
flow through the axial stream of vessels that removes excess procoagulants
from the injury site. Further platelet aggregation is inhibited by prostaglandin
PGI2 released from the endothelium. Endothelial cells and tissues contain
fibrinolysis activators (e.g. tissue plasminogen activator t-PA) that activate
plasminogen to plasmin - an effective proteolytic enzyme capable of clot
lysis. Fibrin degradation products in turn inhibit the effect of thrombin and
fibrin polymerisation. Tissue Factor Pathway Inhibitor (TFPI) inhibits further
production of Factors Xa and IXa by the TF-factor Vila complex.

1.2

Thrombophilia, Venous Thrombosis and Pulmonary Embolism
According to the Haemostasis and Thrombosis Task Force of the British
Society for Haematology, thrombophilia is a term used to describe the familial
or acquired disorders of the haemostatic mechanism which are likely to
predispose to thrombosis (Davidson et al., 1990).

Thrombosis occurs when activation of blood coagulation overwhelms the
ability of the natural anticoagulant and fibrinolytic mechanisms to prevent
inappropriate thrombus formation.

Pulmonary embolism is a feared complication of venous thrombosis. Most
thrombi that cause clinically relevant pulmonary emboli originate from the
pelvic, abdominal and femoral deep veins and occasionally from axillary
thromosis and rarely from the right heart. The thrombus becomes dislodged
and embolizes into the pulmonary arterial system. Consequently, the lung
tissue becomes ventilated but not perfused and this results in defective gas
exchange. Soon after, lung surfactant is no longer produced and alveoli
collapse leading to an exacerbation of hypoxaemia. Ultimately there is a
reduction in cardiac output (Kumar et al., 1998).

Most fatal emboli arise from deep vein thrombosis (DVT) in the lower limb.
A relatively recent study in a general hospital in the United Kingdom showed
that 0.9% of all admissions died resulting pulmonary embolism (Lowe et al.,
1992). Deep vein thrombosis and pulmonary embolism account for 300,000
to 600,000 hospitalisations and 50,000 deaths in the United States annually
(Ens et al., 1995). Fatal pulmonary embolism occurs in about 2 in 1000
postoperative patients each year (Verstraete, 1997). Furthermore, DVT is
difficult to diagnose clinically and its frequency has, therefore, been
underestimated.

1.2.1

Risk of Thromboembolism

Over the past number of years, a number of risk factors associated with venous
thromboembolism have been identified on both a research and empirical basis.
The following table outlines such risk factors:

Background Factors

Disease or surgical procedure

Age >40 years

Trauma or surgery, especially of pelvis, hip.

Severe Obesity

and lower limb

Immobility (bed rest >4 days)
Pregnancy

Malignancy, especially pelvic or abdominal
metastatic

Puerperium

Heart failure

High dose oestrogens

Recent myocardial infarction

Previous DVT or pulmonary embolism

Paralysis of lower limb(s)

Thrombophilia:

Severe infection

Deficiency of ATIII, protein C, protein S

Inflammatory bowel disease (IBD)

Activated protein C resistance,

Nephrotic syndrome

Factor V Leiden
Phospholipid antibody or lupus
anticoagulant
Homocystinaemia

Polycythaemia
Paraproteinaemia
Behcet’s disease
Paroxysmal nocturnal haemoglobinuria
(PNH)

Table 1.1:

Risk factors for venous thromboembolism (Lowe et al., 1992;
Verstraete, 1997)

A widely quoted classification of the degree of thrombotic risk in hospital
patients is given according to the Thromboembolic Risk Factors (THRIFT)
consensus group:

Deep vein

Proximal vein

Fatal pulmonary

thrombosis

thrombosis

embolism

<10%

0.4%

<0.2%

Moderate risk sroups

10-40%

2-4%

0.2-0.5%

Hish risk groups

40-80%

10-20%

1-5%

Low risk srouDS

Minor surgery (<30 min); no risk factors other than age
Major surgery (>30 min); age <40 y; no other risk factors

Low risk groups

Minor trauma or medical illness
Major general, urological, gynaecological, cardiothoracic, vascular,
or neurological surgery: age >40 y or other risk factor
Major medical illness: heart or lung disease, cancer, IBD
Moderate risk groups

Major trauma or burns
Minor surgery, trauma or illness in patients with previous DVT,
pulmonary embolism, or thrombophilia
Fracture or major orthopaedic surgery of pelvis, hip, or lower limb
Major pelvic or abdominal surgery for cancer
Major surgery, trauma, or illness in patients with previous DVT,
pulmonary embolism or thrombophilia

High risk groups

Lower limb paralysis (for example, hemiplegic stroke, paraplegia)
Major lower limb amputation

Table 1.2:

Incidence of venous thromboembolism in hospital patients
according to the THRIFT consensus group (Lowe et al., 1992)

1.2.2

Treatment of venous thromboembolism
The only effective treatment is prevention and prophylaxis should be offered
to all patients at risk.

Prophylaxis of venous thromboembolism
Prophylaxis includes various mechanical and pharmacological methods:

Mechanical Methods

Pharmacological Methods

Graduated compression

Low dose subcutaneous heparin

(TED = Thromoembolic deterrent)

Low molecular weight heparin (LMWH)

stockings.

Oral anticoagulants
Dextran 70

Intermittant pneumatic compression

Antiplatelet agents

devices

Drugs stimulating endogenous fibrinolysis

Table 1.3:

Common methods of prophylaxis aimed at preventing
thromboembolism

By applying the greatest pressure at the ankles and progressively less along the limb,
graduated compression stockings aid blood flow from distal regions of limbs.
Pneumatic compression devices help pump blood around limbs at timed intervals.

•

Antithrombotic drugs are not appropriate for low risk patients
(see Table 1.3 above) and elasticated stockings should be used.

•

For medium risk patients antithrombotic drug treatment should
be used often combined with mechanical methods.

•

In high risk patients, low molecular weight heparins are the
most effective drugs.

Upon consideration of risk factors for venous thrombosis as illustrated
(Table 1.1), it is likely that the prevalence of DVT will increase in future
because the average age of the population and the number of cancer patients is
increasing (Verstraete, 1997). Test patients selected for this study were all
confirmed or suspected cancer patients undergoing various surgical procedures
in the thoracic region. It is anticipated that any conclusions drawn from this
research therefore will be of great importance from both a clinical and
laboratory standpoint in the future, especially with regard to perioperative
venous thrombosis vigilance (Bauer, 1995; Margaglione et al., 1998)

1.3

Thrombosis and Cancer
The association between abnormalities of haemostasis, in particular
thrombosis, and malignancy has been recognised since the 19^*' century
(Glassmann et d., 1994). The presence of fibrin surrounding histological
sections of tumours provides further evidence of a relationship between
coagulation and cancer (Patterson and Ringenberg, 1990; Green and
Silverstein, 1996). The incidence of perioperative DVT in cancer patients
undergoing surgery is consistently elevated with respect to procedures in
patients without malignancy (Schwartz and Simantov, 1988).
Thromboembolism occurs more commonly in the post operative state in
cancer patients compared with the general population (Kempin, 1997).

The problem with determining the precise cause of thrombosis in cancer
patients is that numerous predisposing factors are often present such as
advanced age and the fact that cancer patients are often post-recent surgery
and/or immobilised for long periods. Three mechanisms involved in the
pathophysiology of thrombosis in cancer were outlined by Rickies et al.,
(1988):

•

Platelet activation by tumour cells leading to adhesion or
aggregation (Nand et al., 1990)

•

Procoagulant generation by tumour cells i.e. the production of
proteins by malignant cells that activate coagulation including a
tissue factor-like protein and an activator of Factor X.

•

Production of procoagulants by inflammatory cells such as
monocytes and macrophages.

In addition, direct tumour invasion of veins is a potential trigger of
inappropriate thrombosis.

Routine tests such as the Prothombin time (PT) and Activated Partial
Thromboplastin Time (APTT) are generally not helpful in the diagnosis of

hypercoagulability in cancer (Francis et al., 1994). Prolonged clotting times
usually indicate the presence of decompensated intravascular coagulation.
Paradoxically, it is not uncommon for low PTs and APTTs to be present. The
most common clotting abnormalities in cancer, however, are elevated levels of
Fibrin Degradation Products (FDPs), thrombocytosis and
hyperfibrinogenaemia (Bick ^ al., 1992; Schwartz et af., 1998). Prolonged
PTs, the elevation of specific clotting factors and decreased levels in
coagulation inhibitors including ATIII, protein C and protein S are known in
several carcinomas and other neoplasms (Glassmann and Jones, 1994)

Adequate perioperative anticoagulant prophylaxis is essential in cancer-related
surgical scenarios to reduce thrombotic complications, avoiding undue
haemorrhagic risk.

1.4.

Coagulation and Metastasis
It is has been suggested previously that the mechanisms involved in
hypercoagulability in cancer are identical to the mechanisms involved in
metastasis. Tumour cells release plasminogen activator that generates local
proteolytic activity. This may facilitate the tumour cells by degrading the
basement membrane and connective tissue barriers that naturally prevent
tumour migration (Nand and Messmore, 1990). It has Ibeen proposed that
platelets contribute to metastasis by prolonging the tim(e in which tumour cells
remain within the vasculature and by the adhesion of pllatelet-tumour thrombi
to subendothelial matrices (Dvorak et al., 1981).

The link between coagulation and cancer metastasis as outlined suggests that
careful monitoring and control of coagulation has the potential to prevent
complications, abrogate metastasis and potentially prohong survival.
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1.5

Thrombophilia Screening
A thrombophilia screen is composed of a series of laboratory tests used to
investigate patients with a predisposition to thrombosis. It generates useful
data for consideration of appropriate management during future at-risk
situations both for the patient and for asymptomatic relatives identified
through family studies.

1.5.1

Patient selection for Thrombophilia Screening

The following is a list of indications prompting an investigation for
thrombophilia (Wilde, 1995):
Venous thrombosis or thromboembolism before the age of 45 years
Recurrent venous thrombosis or thromboembolism
Family history of thromboembolism
Neonatal thrombosis
Venous thrombosis at unusual sites (e.g. hepatic, portal, or retinal vein)
Recurrent superficial thrombophlebitis
Recurrent abortion
Arterial thrombosis under the age of 30 years
Arterial thrombosis without arterial disease
Venous thrombosis during pregnancy
Venous thrombosis when using oral contraceptives

1.5.2

Laboratory tests used in Thrombophilia Screens

Many laboratory tests are available in the elucidation of underlying thrombotic
disorders in patients. The algorithm that follows (Figure 1.2) is a modified
version of that proposed by Donnelly and Rock (1999) outlining the laboratory
investigation of a patient with unexplained thrombosis.
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TTirombotic Patient j

Currera tests involved in afull thrombophilia
screen

Tests that may be
included as part of
thrombophilia screens

PT/APTT/INR

Plasminogen assay

Filxinogen Assay

Plasma Homocysteine
(fasting)

Lupus anticoagulant screen:

Exclude APTT assays.
Factor V Leiden
genome analysis

a) DWT (Dilute Russell Viper Venom Test)
b)APTT using ActinFS
c) APTT using ACTIN FSL

Prothrombin G20210A
genome analysis

Antidirombin III assay
Platelet neutralisation

Protein C assay
Protein S assay
PCA Test for APC resistance
Cardiolipin antibody investigation

MTHFR C677T genome analysis.
Folate, B12 assays

Yes

Figure 1.2:

Folate, and B12 within reference intervals?
MTHFR 677C/t or CC,
Creatinine clearance NORMAL?
Drug induced homocysteinaemia ruled out'’

Laboratory investigation of a patient with unexplained venous thrombosis. Green
regions are the current tests performed as part of a full ‘thrombophilia screen’ when
specifically requested. White regions are currently not part of ‘routine’
thrombophilia screens in most hospital laboratories, but are available from specialist
centres.

(Note: INR = International Normalised Ratio; PCA = Protein C Activator; A PC

=

Activated Protein C)

An activated protein C resistance (APCr) phenotype may be detected using activated
partial thromboplastin time-derived (aPTT) plasma assays (Dahlack ^ a]., 1993).
Generally, it involves the measurements of the aPTT in both the presence and absence
of a standardised amount of activated protein C. These measurements produce an
APC-sensitivity ratio (APC-SR) (De Stefano and Leone, 1995). Typically, an APCSR ranges between 1.8-2.3 in the absence of APCr due to Factor V Leiden. Patients
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heterozygous for the allele usually have APC-SR values between 1.4-1.7.
Homozygous abnormal patients for Factor V Leiden have APC-SRs of just over 1.0
(Dahlback et al., 1996)
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1.6

Thromboelastography
Thromboelastography (TEG) was originally described by Hartert in 1948, and
measures haemostasis as a whole dynamic process (Ames et a]., 1999).
Although not widely available in Ireland, TEG is increasingly being used in
clinical practice in the U.K. to evaluate the viscoelastic properties of whole
blood during the perioperative period. This approach offers the potential for
significant cost savings on blood and related blood products in the hospital.
The TEG is a small instrument that can be set up easily in the operating theatre
or anaesthetic room.

1.6.1

How does the TEG measure haemostasis?
The TEG is composed of a number of ‘channels’. Each channel contains a
heated (37°C) cuvette or cup which oscillates slowly, and a pin that is
suspended freely from a torsion wire (Figure 1.3). Blood is drawn from a
patient and within 4 minutes (maximum time limit) is placed in the cup.
Before blood clotting begins, the sample remains liquid and the motion of the
cup does not affect the pin. As soon as the first fibrin strands begin to form
the motion of the oscillating cup is consequently conducted to the pin. The
viscoelastic properties of the clot in this way is transmitted through the pin and
displayed graphically over time in the form of a TEG trace on a visual display
unit or on paper (Francis et d., 1994; Ames ^ ^., 1999)

Figure 1.3: Principles of Thromboelastography

Several TEG parameters/indices are also provided that aid in the analysis and
interpretation of the TEG (Table 1.4).
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Normal Range

Parameter

Explanation

r = reaction time

6-8 minutes

Time taken for initial fibrin formation.

K = clot formation

3-6 minutes

A measure of the speed of fibrin formation.
(measured from r time to point where amplitude

time

of the tracing reaches 20 mm)
a = alpha angle

50°-60°

Speed of clot strengthening, a function of
fibrinogen

MA = maximum

50-60 mm

amplitude

Reflects the strength of the fibrin clot. Depends
on platelet function and number, fibrinogen and
Factor XIll levels.

Lys 30 = Lysis 30 min.

It is a measure of clot lysis retraction.

Lys 60 = Lysis 60 min.

It is a measure of clot lysis retraction.

TEG index

Value representing the entire dynamic of the
coagulation system

Table 1.4:

Summary of TEG parameters used in coagulation analysis
(Traverso et al., 1995). See also Figure 1.4.

How these parameters are obtained from the TEG tracing is illustrated in
Figure 1.4:

NATIVE THROMBELASTDGRAPHIC TRAONG

Figure 1.4:

A representative native (whole blood)
thromboelastographic tracing illustrating the measured
variables outlined in Table 1.4.
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1.6.2

Advantages of the TEG
•

A single blood sample can provide information from the earliest stages
of platelet interaction with fibrin, platelet aggregation, clot
strengthening, fibrin cross-linkage and clot lysis (A summary of typical
TEG traces is provided in Figure 1.5).

•

Relevant data can be obtained within 20-30 minutes

•

The TEG provides information relating to fibrinolytic activity and
platelet function that is not generally available from routine
coagulation screens. Standard laboratory clotting measurements end
with the formation of the first fibrin strands (Zuckerman ^ d., 1981).

•

It is easy and practical, for use in an operating theatre or anaesthetic
room.

•

It may be used to determine the effect of haemostatic drugs in vitro
before administration to the patient.

•

TEG-guided therapy can decrease the use of empirical therapy and
excessive transfusions during surgery (Kang et al., 1989).

•

Thromboelastography performed in decalcified whole blood may
reflect preoperative hypercoagulability in elective abdominal surgery,
which could identify patients at risk for developing DVT (Traverso et
ai., 1993).

Figure 1.5:

Specific haemostatic defects displaying characteristic TEG traces;
A = normal trace, B = Haemophilia (prolonged r and K times), C =
Thrombocytopenia (normal r and K times, decreased MA), D =
Fibrinolysis, E = Hypercoagulability (short r time, increased MA,
large alpha)
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1.7

Genetic risk factors for venous thrombosis
A familial tendency towards venous thrombosis may be explained by one or
more genetic risk factors. The common genotypes and mutations associated
with an increased risk for thrombosis are summarised below, including those
that were investigated in both the control and test populations in this project.

1.7.1

Factor V Leiden
In 1993 Dahlback et al reported a novel hereditary defect leading to a
hypercoagulable state that was characterized by poor anticoagulant response to
activated protein C (Dahlback et al., 1993; Koster et al., 1993). Subsequently,
Bertina et al., (1994), identified the mutation in the human blood coagulation
factor V gene (Jenny et ^., 1987), the factor V Leiden allele, that influenced
the activated protein C (APC) pathway.
Thrombin, only in the presence of thrombomodulin, activates protein C.
Activated protein C limits clot formation by proteolytic modification of factors
Va (at Arg^^^, Arg^^^ and Arg^^^) and Villa in conjunction with a
nonenzymatic cofactor protein S (Dahlback ^ al, 1994; Kalifatis and Mann,
1997; Maher et al., 1997). The 1691 A->G missense transition mutation in
exon 2 of the factor V gene (located on chromosome 1 [q21-25]) results in the
substitution of arginine for glutamine at amino acid position 506 (i.e. R506Q).
As a consequence of this Factor V Leiden mutation, the rate of FVa:Q506
inactivation by APC may be 10 to 20 times lower than the rate of FVa:R506
degradation and therefore leads to a hypercoagulable state (Rosendaal et al,
1995; Hillarp ot al., 1996; Dahlback ^ al., 1997)
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Figure 1.6:

Activation and inactivation of Factor V (Dahlback ^ d., 1996).
Human Factor V is a large single-chain glycoprotein, 2196 amino
acid residues in length, organised in the domain order Al, A2, B,
A3,C1,C2.

Individuals that are heterozygous for the factor V Leiden allele have an
associated 5- to 10-fold risk of thrombosis. Patients with the homozygotic
abnormal genotype have a 50- to 100-fold increased risk.

Prevalence of APC resistance (APCr) and Factor V Leiden:
APC resistance is the most prevalent coagulation abnormality associated with
venous thrombosis occurring in 20 to 65% of patients with a history of
familial venous thromboembolism (Zoller et al., 1996; Maher et al., 1997).
Factor V Leiden accounts for more than 95% of cases of APCr and its
prevalence in the general population of Western countries ranges from 2% to
15% (Rees et al., 1995; Herrmann et al., 1997; Pepeetal., 1997).

Owing to such a high prevalence of the Factor V Leiden allele, affected
patients that possess other genetic or environmental risk factors predisposing
to thrombosis (Table 1.1), have a greatly increased risk of developing a
thrombotic episode (Hellgren et al., 1995; Zighetti et al., 1997; Alhenc-Gelas
et al., 1999;Salomon et al., 1999; Walker, 1999). In addition it has been
suggested that the factor V Leiden allele plays a minor role in the
hypercoagulable state of cancer (Otterson et al., 1996).

1.7.2

Methvlenetetrahvdrofolate Reductase (MTHFR) C677T
Hyperhomocysteineniia has been identified as a risk factor for arteriosclerosis
and thrombosis (Adams ^ a]., 1996; Kluijtmans ^ al., 1996; Margaglione et
d., 1999). MTHFR is an important enzyme in homocysteine metabolism (see
Figure 1.7) that catalyses the reduction of 5,10-methylene tetrahydrofolate to
5-methyltetrahydrofolate, the predominant circulating form of folate (Goyette
et al., 1994). In 1988, a new variant of MTHFR with thermo labile properties
and reduced enzyme activity with consequent mildly elevated plasma
homocysteine levels was described (Kang et a]., 1988; Balasa et al., 1999).
Frosst ^ ^., (1995) subsequently identified a common genetic C^T transition
at nucleotide position 677 resulting in the incorporation of a valine for an
alanine amino acid at the protein level. This mutation generates a
thermo labile form of MTHFR that exhibits approximately 50% of normal
enzyme activity and was identified as a candidate risk factor for vascular
disease (Frosst et d., 1995).

Figure 1.7:

Biochemical Pathway in Folate Metabolism {adaptedfrom
BartiseloL; 1999)
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The following table (Table 1.5) illustrates the prevalence of the C677T
MTHFR gene mutation in different ethnic groups:

% Heterozygote

% Homozygote

MTHFR

MTHFR

Caucasians

52.9

9.8

Asians

40.0

20.0

Amerindians

32.5

7.8

African Blacks

10.4

0.0

Brazilian Blacks

20.0

2.0

Colombians

46.7

25.0

Ethnic Group

Table 1.5:

Prevalence of the MTHFR C677T allele in various racial
groups (Vanegas et al., 1998).

The prevalence of the heterozygote allele in the Caucasian population is more
than five-times higher than in the African Negro population, with other groups
having a prevalence of the allele ranging between 10% and 52.9%. There is
also a large spread in the frequency of homozygosity. These figures may
reflect an adapted genetic alteration in response to the different environments
of these racial groups e.g. different diets and folate metabolism.

Although homozygosity for the MTHFR 677T allele has been shown to
convey a 3-fold risk for premature vascular disease, its involvement in the
development of venous thrombosis remains unclear (Bowen ^ ^., 1998;
Kluijtmans et al., 1998; Hessner et al., 1999).

The genetic risk factor MTHFR C677T is thought to interact with
environmental factors such as a deficiency of folic acid resulting in
hyperhomocysteinemia (Markus et al., 1997). It may be that the combined
effects of the genetic polymorphism together with environmental factors are
key to the predisposition to thrombosis. It is important to note however, that
elevated levels of homocysteine due to this mutation can be normalised by
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administering vitamins involved in homocysteine metabolism, especially
folate (Blom, 1998).

1-7.2.1 Homocysteine as a cause of inappropriate thrombosis
Homocysteine may contribute to the thrombotic process by affecting vascular
cell proliferation and promoting prothrombotic activites in the vascular wall
(Morita et al-, 1997). It has been reported that homocysteine inhibits
thrombomodulin surface expression, protein C activation, tissue plasminogen
activator binding and anticoagulant heparan sulphate expression in endothelial
cells and enhances endothelial cell-associated factor V activity (Rodger and
Kante, 1986; Lentz et al., 1991). Homocysteine has also been shown to
increase thromboxane Aj formation in platelets which is involved in platelet
activation.

Possible beneficial effects of the C677T mutation include the association of
the valine allele with lower blood pressure (Nakata et al., 1998). Of particular
relevance to this project are reports that the mutated allele may protect the
tumour suppressor gene pl6INK4 thereby affecting carcinogenesis (Kamiya et
al., 1998). Other reports suggest that the risk of colon cancer is significantly
reduced in individuals homozygous for the mutation (Pereira ^ al., 1999). It
is well known that folate derivatives are essential for DNA synthesis and
methylation. The presence of the mutation may offer a natural
protection/preventative mechanism against carcinogenesis due to increased
levels of methylenetetrahydrofolate. This form of folate is required for the
formation of deoxythymidine monophosphate (dTMP) from deoxyuridine
monophosphate (dUMP) ensuring the fidelity of DNA replication by
limiting/preventing the mis-incorporation of dUTP (Green et ai., 1999).
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Dietary Folc Acid
(potyc^tamates)

1

(mono^^tamates)

piasma
5-MeTHF

Figure 1.8:

A biochemical pathway illustrating the relationship between Folic acid,
Methylenetetrahydrofolate and DNA. {Adapted from Kaplan el ql.,
1984)
Notes: DHF, Dihydrofolate; DNA, Deoxyribonucleic acid; dUMP, deoxyuridine
monophosphate; FIGLU, formimino-L-glutaric acid; F-THF, folinic acid; 5-MeTHF,
N-5-methyltetrahydrofolate; MeB12, methyl cobalamin; THF, tetrahydrofolate;
TMP, Thymidine monophosphate.

1.7.3

Factor XIII Val34Leu
Blood coagulation factor XIII when activated to become factor Xllla is a
protransglutaminase (E.C. 2.3.2.13) that cross-links fibrin in the last steps of
the coagulation cascade. Not only does factor Xllla promote the formation of
peptide bonds interlinking the glutamine side chain of one fibrin monomer
with the lysine side chain of a second, but also protects fibrin from the
fibrinolytic enzyme plasmin. Hence it is often referred to as “fibrin stabilizing
factor” (Muszbek ^ d., 1996).

In 1994, a mutation in the blood coagulation factor XIII was described in a
Finnish population (Mikkola ot ^., 1994). This mutation involved a G-a-T
transversion in exon 2 of the FXIII A-subunit, resulting in the substitution of
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leucine for valine at amino acid position 34 (FXIIIVal34Leu). The
polymorphism occurs 3 amino acids on the N- terminal side of the FXIII
activation site (see Figure 1.9) and therefore may contribute towards more
efficient activation of FXIII and interfere with fibrin cross-linking (Ichinose et
al., 1986; Ichinose and Davie, 1988; Kohler et^., 1999). Consequently, since
several genetic abnormalities are known to be major risk factors for venous
thrombosis, the FXIIIVal34Leu mutation has recently been added to these and
may represent another possible genetic risk factor (Catto et al., 1998; Catto ^
d., 1999; Franco^a]., 1999).

Va(34Leu
(G^o-T)

i

Thrombin Activation
Arg

Thrombin Inactivation

-Gly
Cys-His-Asp catalytic triad

NH2

^ 314
Cys

T\

i

A

Arg
p-Sandwich
(140 residues)

... 373 . 396
His
Asp

i

i

i

Central Domain (core)
(330 residues)

Barrel 1 and 2
(211 residues)

COOH

Activation Pcptide^^
r.ly-38 Glu-43

Phe-IM Asn-185

Arg-SIS Ser-516

FXIII A-subunit polypeptide

Figure 1.9:

Overview of the FXIIIA-subunit showing the thrombin
activation site and the position of the FXIII Val34Leu
polymorphism (adaptedfrom Kohler et gl., 1998a).

The prevalence of the FXIII T-allele in many populations has yet to be
measured. Table 1.6 provides genotyping details of some population groups:

FXIIIVaI34Leu

FXIIIVal34Leu

% Heterozygote

% Homozygote

Healthy Caucasians

41.0

7.0

Pima Indians

i8.0

16.0

Asian Indians

17.5

3.75

Table 1.6:

Prevalence of the Factor XIIIVal34Leu allele in various
populations (McCormack ^

1998)
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Although the statistics are few, the data shown in Table 1.6 demonstrate a
large variation in the prevalence of the allele among racially distinct groups.

It is well established that only 0.5% to 2% of normal FXIII levels are
sufficient to achieve normal haemostasis (Milozewski and Losowsky, 1988;
Anwar et al., 1999). The worldwide frequency of FXIII deficiency was
estimated at 1 patient in 2 million (Mikkola et al., 1994). The local FXIII
concentration is increased at sites of injury due to platelet activation. The
formation of large fibrin clots in such regions may significantly influence
pathological thrombotic and thromboembolic episodes especially in
individuals with high plasma FXIII concentrations. This would be of concern
for patients with the Leu-34 allele, as FXIII plasma levels tend to be raised in
patients with this allele (Kohler et al., 1998b; FJbaz et al., 2000).

Plasma FXIII levels are becoming accepted as an important marker of disease
activity in various inflammatory conditions including Crohn’s disease,
ulcerative colitis and bacterial infection as well as in patients with benign and
malignant gynaecological tumours where low levels of FXIII were found
(vanWersch et al., 1994). Since it has been shown that FXIII levels are not a
direct indicator of FXIII enzymatic activity (Anwar et d., 1999), both the
factor’s activity and circulating concentration must be determined for use as a
diagnostic marker of disease. Interestingly, an association between the
FXIIIVal34Leu allele and reduced risk of myocardial infarction has recently
been reported (Wartovaara et al., 1999).

1.7.4

Protein C, Protein S and Antithrombin III deficiency
Until the identification of the Factor V Leiden mutation, genetic defects of
protein C, protein S and antithrombin III accounted for the majority of known
causes for familial venous thromboembolism. Between them, however, these
abnormalities are found in less than 5-10% of patients with thrombosis (Lane
et al., 1993; Hillarp et al., 1995; Rosendaal et al., 1997).
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For the detection of protein C, protein S and antithrombin III deficiencies,
functional and/or immunological tests are essential. As illustrated in
Table 1.7, genetic defects leading to deficiencies are too heterogeneous for
genetic testing in routine diagnostic procedures to be worthwhile (Aiach et al.,
1995 and 1997; Bertina, 1997). Since protein C, protein S and
antithrombin III are vitamin K-dependant proteins, patients on oral
anticoagulant therapy are unsuitable for functional assays. Such therapy must
be discontinued for at least one week prior to functional analyses of samples
from these patients (MacHale ^ d., 1997).

Phenotype

Prevalence (®/o)

No. of mutations

APC resistance

45

1 (Factor V Leiden)

Increased Prothrombin

18

1 (Factor IIG20210A)

Protein C deficiency

5.7

>160

Protein S deficiency

5.7

>69

Antithrombin III deficiency

4.3

>79

Table 1.7:

Genetic defects in inherited thrombophilia

Generally these deficiencies are inherited as autosomal dominant traits and
homozygotes usually die in utero (Murin ^ d., 1998)

Deficiencies may be divided into two types:
Type I: Low plasma levels of the proteins.
Type II: Low functional levels of the proteins (due to abnormal molecule).

A rare third type of deficiency has been identified in protein S that according
to the International Society on Thrombosis and Haemostasis (ISTH)
standardisation committee is characterised by low free protein S levels with
normal or subnormal total protein S levels (Aiach et al., 1997).

Antithrombin is the most important physiological proteinase inhibitor of
coagulation accounting for approximately 80% of the thrombin inhibitory
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activity of plasma (Perry ei al., 1994). Not surprisingly deficiencies in
antithrombin appear to be more severe than deficiencies of protein C or S
(Perry and Carrell, 1996; Rosendaal et al., 1997)

Genetic defects of antithrombin III and protein C were investigated in this
project using Restriction Fragment Length Polymorphism analysis as designed
and described by Maher, (1998).

1.7.5

Prothrombin G2Q210A
Prothrombin (or blood coagulation factor II) is the precursor of the serine
protease thrombin (factor Ila) that plays a vital role in haemostasis. A
‘prothrombinase’ complex consisting of phospholipid, factor Xa, factor Va
and Ca^^ ions activates prothrombin to the active thrombin as part of the
common pathway of the coagulation cascade (see Figure 1.1).

In 1996, Poort ^

described a common genetic mutation in the

3'-untranslated region of the prothrombin gene (Friezner-Degen et al., 1987).
This G-^A mutation at nucleotide position 20210 is associated with elevated
plasma prothrombin levels and, therefore, an increased risk (up to 5- fold) of
thrombosis (Gumming et al., 1997; Makriset al., 1997; Rosendaal et ^.,
1997). The mechanism by which this base substitution contributes to higher
plasma prothrombin levels remains unclear. Possibilities include effects upon
gene regulation such as a higher translation efficiency or greater stability of
the transcribed mRNA.

The prothrombin 202 lOA allele is one of the most prevalent genetic factors
associated with venous thrombosis estimated at about 2-3% in the healthy
population and between 5-6% of unselected patients with venous thrombosis
(Poort et al., 1996; Brown et al., 1997; Murin et al., 1998). Subjects that
possess the faetor V Leiden allele, and/or deficiencies in protein C, protein S
and ATIII and who have had a venous thromboembolism are significantly
more likely to earry the 202 lOA allele compared with controls. Coinheritance
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with other familial risk factors greatly increases the overall risk of thrombosis
in patients.

What makes this mutation different from the other mutations associated with
thrombosis is that the laboratory diagnosis relies entirely on DNA analysis. It
cannot be reliably diagnosed by standard functional or immunological tests
(Bertina, 1997).
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1.8

Methods of Genomic Analysis

1.8.1

Overview of the Polymerase Chain Reaction (PCR)
The polymerase chain reaction is an in vitro technique that amplifies specific
segments of DNA. Following its development in 1985 by Kary Mullis (Mullis
^ al., 1986 and 1987), the number of applications reported for PCR together
with novel design modifications has grown exponentially (Fanning and Gibbs,
1997). Polymerase chain reaction is capable of very high sensitivity of
molecule detection and is therefore a favourable practical technique in that it
obviates the need to use hazardous radio-isotopic detection systems that were
more commonly used.

Some mutation detection and identification techniques depend upon the actual
PCR itself, while others require analysis of the amplification products. The
way in which PCR and various post-amplification techniques were applied in
this project will be outlined below.

1.8.2

Summary of the Polymerase Chain Reaction
The in vitro enzyme-mediated amplification of target DNA by PCR is
comprised of a repetitive series of cycles (Figure 1.10). A single cycle
involves three steps:
1)

duplex DNA template denaturation

2)

annealing of oligonucleotide primers that hybridise to opposing
strands with the template flanking the region of interest and

3)

extension of annealed primers by a thermostable DNA
polymerase

A summary of the conditions for steps 1) through 3) is given in Table 1.8.
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Figure 1.10:

Overview of the PCR reaction (Diagram modified from
Fanning and Gibbs, 1997.)
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Typical Reaction Parameters

Step
Denaturation

Initially, temperatures of 92-96°C for 3-5 min ensures DNA template is completely
denatured. In subsequent steps, denaturation lasts for about 1 min to prevent loss of
enzyme activity.

Annealing

Primers anneal to complementary sequences at temperatures ranging from 40-70°C.
This temperature is typically 5°C below the Tmf (melting temperature) of the target
sequence.

Extension

Taq DNA polymerases extend annealed primers in a 5' to 3' direction to form nascent
DNA strands. Optimal temperatures for the enzyme are between 70-75°C.

Table 1.8:

Summary of the general parameters used during the three steps
in the PCR cycle.
f Tm may be estimated theoretically using Sugg’s equation:
4(G + Q + 2(A + T)
...where A, T, G and C represent the number of respective bases in the
target sequence.

If PCR was to be 100% efficient, one target molecule would become 2^ after n
cycles. In practice, 20-40 cycles are commonly used.
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1.8.3

Reagents required for successful PCR
There is no one ‘standard’ reaction mixture that is suitable for all PCRs. Some
reagents/materials are of course essential, but since target sequences may
differ in length, base composition and arrangement, modifications in reaction
conditions are often necessary. Consequently, a number of reagents have been
used in PCRs whose properties contribute to a successful PCR (Table 1.9):

Properties

Reagent/Material
Template DNA

Of good quality when extracted from the buffy coats of centrifuged blood samples (5-10
fold DNA yield than from whole blood) using commercial DNA extraction kits.

Oligonucleotide

These are often between 18-30 bp in length with similar GC content. Important in

Primers

primer design is correct base pairing at the 3'-end. Deliberate modifications at the
5'-ends of primers may be used to aid mutation detection (see Factor V Leiden,
Section 1.7)

Thermostable DNA

Essential for 5'->3' exonuclease activity. Optimal concentrations range from 1-2.5 units

Polymerase

per 100 |i reaction volume. Taq DNA polymerase from the thermophilic bacterium
Thermus aquaticus was used in this project. Many others are available from other
organisms such as Thermococcus litoralis, Thermus thermophilus, Pvrococcus furiosus
each with their own characteristics (Fanning and Gibbs, 1997).

MgCb

Important for enzme activity - it helps to increase the Tm of dsDNA and fornis soluble
complexes with dNTP that are essential for dNTP incorporation. Concentrations of
about 1-4 mM are usually optimal.

dNTPs

Essential for incorporation into nascent DNA strands. Optimal concentrations range
between 50-200 gvi of each dNTP.

PCR Buffer

These may vary greatly but often contain Tris-HCl and KCl. Functions can include
maintaining pH at optimal levels, facilitating primer annealing, aiding dNTP
incorporation and fidelity of enzyme.

Dimethylsulfoxide

A strong denaturant. Very useful in regions that are GC-rich. Reduces secondary

(DMSO)

structure of target DNA. May inhibit Taq polymerase.

Bovine Serum

Helps stabilise Taq DNA polymerase and chelate inhibitors.

Albumin (BSA)
Triton X-100

Helps stabilise Taq DNA polymerase.

Gelatine

Helps stabilise Taq DNA polymerase and chelate inhibitors.

B-mercaptoethanol

A reducing agent that eliminates primer secondary structures and reduces disuphide
bonds of any inhibiting proteins in the reaction.

Table 1.9:

Summary of the essential (indicated by shaded regions) and
adjunctive reagents that were used for successful PCR.
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1.8.4

Restriction Fragment Length Polymorphism (RFLP) analysis
Restriction enzymes are endonucleases that are derived from bacteria. They
have the ability to cleave both strands of double stranded DNA within
particular recognition sequences.

Occasionally, mutations create or destroy restriction endonuclease target sites
and this enables simple diagnosis of the mutation by gel electrophoresis
following enzyme digestion of any PCR product. DNA fragments of different
sizes generated by digestion with the appropriate enzyme (depending on the
presence or absence of a mutation) gives rise to the term “Restriction
Fragment Length Polymorphism” analysis. The identification of the C677T
mutation within the MTHFR target sequence (in this study) with HinfT
restriction enzyme is an excellent example of this simple, yet invaluable,
diagnostic tool (Adams et al., 1996; Markus et al., 1997; Wisotzkey et al.,
1999) (see Figure 1.11).

MTHFR Wild Type allele
nt 677 = C
No Restriction Site for Hinfl

MTHFR mutant allele
nt 677 = T
Restriction Site for Hinfl created

Figure 1.11:

Creation of a restriction enzyme recognition site by base
substitution in the MTHFR gene.

Situations arise, however, when a mutation does not lie within or near a
suitable endonuclease restriction site. Therefore, direct RFLP analysis is not
possible. To overcome this, Site-Directed Mutagenesis (SDM) PCR may be
used.

1.8.5

Site-Directed Mutagenesis (SDM) PCR
Sometimes referred to as “primer-introduced restriction analysis”, a base
change close to the position of the known mutation is introduced by creating a
deliberate mismatch in the PCR primer design. This creates a restriction
enzyme recognition sequence. Restriction enzyme digestion of amplified
fragments is then possible following PCR. Agarose gel electrophoresis is then
used to determine the presence of a mutation. Genomic analysis of the factor
V Leiden allele (in this project) with Hindlll, illustrates the usefulness of this
technique (Gandrille et a]., 1995)(see Figure 1.12).

Wild Type:
- CTgTCCgCAg TACAg
^---------------TCgAAATgTC

Target DNA strand
Primer

i

PCR Amplify

CTgTCCgCAgCTTTACAgr
gAC AggCgl'C?;/ AT gT C_

Mutant Allele:

- CTgTCCg lAg
TACAg^_________ TCg^^ATgTC-

Target DNA strand
Primer

i

PCR Amplify

CTgTCCg AgCTT TACAg
gACAgg q/TC§AtA ATgTC
Creation of an Hindlll recognition site
Figure 1.12:

A deliberate three-base pair mismatch in a PCR primer. Three bases are
introduced into amplified DNA sequence. An Hindlll cleavage site is formed
only in the presence of the mutant allele. Note: Lower case ‘g’ is used to avoid

confusion with upper case ‘C

Green letters show mutation; ‘hollow ’ letters

show mismatch in primer design
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It is possible to design assays so that multiplex PCR-mediated RFLP analysis
for detecting several mutations in a single tube is achieved. Linfert et al.
(1998) successfully performed and optimised this technique for Factor V
Leiden and Factor II 202 lOA allele genotyping.

1.8.6

Single Stranded Conformational Polymorphism (SSCP) analysis
PCR-based SSCP is a very simple and sensitive technique used to detect point
mutations. First described by Orita et al. in 1989, it has become one of the
most widely used mutation scanning methods.
The principle of SSCP analysis is based not only on the length of single
stranded DNA (ssDNA) but also on the secondary structure (conformation)
assumed by the ssDNA undergoing electrophoresis.

SSCP analysis is peculiar in that a non-denaturing polyacrylamide gel (PAGE)
is used. Following PCR amplification of mutant and wild-type target DNA,
the products are denatured and electrophoresed through the gel. The
non-denaturing property of the gel facilitates the development of
intramolecular interactions within the migrating single strands to occur.
Consequently, the ssDNA molecules from each denatured PCR product
assume a three-dimensional conformation that is dependant upon the primary
sequence of the DNA. Single base changes are sufficient to alter the
secondary structure resulting in a mobility shift. Mutations are therefore
visualised on gels by differential migration from wild-type banding patterns.
It is important to note that SSCP analysis simply detects mutations.
Subsequent DNA sequencing is necessary to identify and characterise any
mutation detected as a fragment shift on a PAGE gel.
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Wild-type sense strand

Wild-type antisense strand

Mutant sense strand

Mutant antisense strand

Figure 1.13: Different conformations of DNA in SSCP analysis.

For successful SSCP analysis amplified fragments should be small, typically
<300 bp, as the sensitivity of detection decreases as fragments increase in size.
On average the technique detects between 70% and 95% of point mutations
(Grompe, 1993).

Detection of the products on gels can be performed using several methods
including silver and ethidium bromide staining and using fluorescent and
radiolabels. Flowever, interpretation of gel patterns can be complicated. In
addition to the single stranded fragments, faster migrating bands of double
stranded DNA (dsDNA) are often detected. The non-denaturing conditions of
the gel allow some reannealing of single strands. These are not insignificant
and can in fact aid in mutation detection by the presence of ‘heteroduplex
shifts’.

Important considerations for successful SSCP include: maintaining a constant
gel temperature, using optimal cross-linking ratios between acrylamide and
bisacrylamide, using correct acrylamide concentrations, correct length of time
for electrophoresis (can depend on fragment length), running of a dsDNA
control to allow distinction between ssDNA and dsDNA bands.
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1.9

Additional mutation detection methods

1.9.1

Heteroduplex Analysis
Double stranded DNA molecules that contain a mismatch are known as
heteroduplexes. These can be separated from homoduplexes on gels and
therefore can be used as a mutation detection system (White et al, 1992;
Grompe, 1993;).

If mutant and wild type DNA sequences are present in a PCR reaction,
molecules may form that are identical to the original ones (homoduplexes) or
hybrid molecules may form (heteroduplexes) during the late cycles. Upon
analysis using regular polyacrylamide gels, homoduplexes migrate according
to size, but heteroduplex migration differs (Nagamine et ah, 1989). This may
be due to the production of a kink or mismatch bubble. This method is simple
to use and has similar sensitivities for mutation detection as SSCP analysis.

1.9.2

Chemical Mismatch and RNase Cleavage
These techniques are similar in that heteroduplexes are involved. As the name
suggests, in Chemical Mismatch Cleavage (CMC) hydroxylamine and osmium
tetroxide react with mismatches in a DNA heteroduplex (Cotton ^ ^., 1988;
Grompe etal., 1989; Forrest et al., 1991; Grompe et al., 1993). This
chemically labelled DNA is then cleaved by piperidine at the site of the
mismatch and electrophoresis on polyacrylamide gels detects mutations on the
basis of DNA fragment sizes.

In RNase cleavage an RNA-DNA heteroduplex is the target for the enzyme
RNase. Amplified DNA from PCR is denatured and annealed with a single
stranded RNA riboprobe. The RNase enzyme recognises the single stranded
RNA at the point of mismatch and cleaves the RNA. Variations in the
generated fragment sizes indicate the presence and location of mutations.

1-9.3

Denaturing Gradient Gel Electrophoresis (DGGE)
This is a highly reliable and rapid method for mutation detection with a
mutation detection rate close to 100% in PCR products up to 600 bp in length
(Gandrille et al., 1992; Grompe, 1993; Hawkins, 1997).

The DGGE system is composed of a gel that contains an increasing
concentration gradient of denaturant (urea and formamide). As fragments
migrate down the gel, strands progressively dissociate once they reach a
critical denaturant concentration (Lerman et d., 1987). This ‘melting’ leads to
a reduction in electrophoretic mobility. Since the melting temperature (Tm) at
particular domains will differ between wild type and mutant alleles, this will
be reflected in electrophoretic band patterns.

The sensitivity of DGGE is enhanced if heteroduplex DNA between wild type
and mutant sequences is used for analysis. ‘GC-clamps’ are often included in
the primer design to ensure that the amplified sequence has a low dissociation
temperature and avoids non-detection of mutations in highest melting domains
(Sheffield et al., 1989).

1.9.4

Allele-Specific PCR amplification
Used for the detection of known mutations, this technique is an example of an
amplification method that does not require post-amplification processes.

Sequence-specific primers are designed, that differ at the 3 '-end, and are used
in two separate PCRs. The wild type allele is amplified only in one reaction
and the mutant allele is amplified in a second reaction. The presence or
absence of a specific PCR product from the reactions is sufficient for allele
assignment i.e. Homozygous normal, heterozygous, homozygous abnormal.

AS-PCR amplification has been successfully used for the detection of the
Factor V Leiden allele (Blascyk et al., 1996) and the FXIII Val34Leu allele
(Henry ^al., 1999)
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This technique may be designed so that simultaneous amplification reactions
can be carried out in one tube. This multiplex allele specific amplification of
DNA fragments has been used to determine MTHFR C677T, Factor V Leiden
and Prothrombin 202lOA genotypes (Hezard et

1.9.5

1999; Maher et d., 1999)

Dot Blots
This technique is very useful for identifying the presence of known mutations.
It is also excellent for genotyping many PCR samples for a single mutation.
Dot blotting (Figure 1.14) is sometimes referred to diS Allele-Specific
Oligonucleotide Hybridisation. Usually PCR product is fixed to a nylon
membrane by means of a vacuum dot blotter. Oligonucleotide probes, labelled
with [y-^^P] ATP molecules at the 5'-end (or some other reporter
group-digoxygenin), that are homologous to the wild type or mutant alleles are
then added to the membrane (Hawkins, 1997). Similar to Southern blotting,
genotyping can be subsequently earned out using autoradiography.

PCR products dotted onto nylon membrane

Homozygous wild-type sample
Heterozygous sample
Homozygous mutant sample

O
O

o

Hybridize to oligonucleotide probe

Figure 1.14:

Typical Dot Blot genotyping mechanism
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This method can be altered so that PCR product from individuals may be used
as the ‘probe’ and the oligonucleotides are immobilised on the nylon
membrane. This is known as a ‘reverse dot-blot’.

Dot blots may be of great value in terms of a screening test for mutations
implicated in predisposition for thrombosis, by facilitating simple, rapid and
cost effective genotyping of several mutations simultaneously.

1.9.6

5'-Nuclease activity, fluorogenic probes and the TaqMan assay
More recent advances in PCR technology include utilisation of the 5'-nuclease
activity of Tag DNA polymerase and fluorogenic oligonucleotide probes in
combination.

In 1991, Holland et al. demonstrated that cleavage of a target probe during
PCR by the 5'-nuclease activity of Tag DNA polymerase could be used to
detect amplification of a target-specific product. Following the development
of fluorogenic probes (Lee et

1993) the Perkin Elmer Applied Biosystems

corporation designed a TaqMan® assay system that uses these two recent
developments for PCR analysis.
Flourogenic 5' Nuclease Chemistry
Polymerization
..

rgnwNflu
FORWAftO
rnmih

_________^ Pwoti

Strand Displacement
(j)..

Polymerization Completed

QUEMCHER

Two fluorescent dyes, a reporter (R)
and a quencher (Q), are attached to
the 5' and 3' ends of a TaqMan® probe.

Figure 1.15:

Cleavage

D.

R-RfPORTER
J.

When both dyes are attached to
the probe, reporter dye emission
is quenched.

During each extension cycie, the
Taq DNA polymerase cleaves the
reporter dye from the probe.

Once separated from the quencher,
the reporter dye emits its characteristic
fluorescence.

Representation of the forklike-structure-dependant,
polymerisation-associated, 5' to 3' nuclease activity of Taq
DNA polymerase acting on a fluorogenic probe during one
extension phase of PCR. (Diagram from Perkin Elmer Applied
Biosystems, Warrington, U.K.)
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The advantages of this system are extremely valuable from a praetieal point of
view. Non-specific amplification due to mispriming or primer-dimer artifact
does not generate fluorescent signal. Different reporter dyes may be used
which allows the possibility of amplification of two distinct sequences in a
single reaction.

Successful use of this technology has been reported by Happich et

(1999)

in the genetic diagnosis of factor V Leiden.

1-9.7

Amplified Refractory Mutation Detection Systems (ARMS^
Any known mutation in Genomic DNA may be detected using a system
known as ARMS (Newton et al., 1989). This simple, rapid and reliable
technique has the advantage over other types analysis involving PCR in that it
allows genotyping solely by inspection of PCR reaction mixtures after agarose
gel electrophoresis.

ARMS works on the principle that oligonucleotides with a mismatched
3 '-residue will not function as primers in the PCR under appropriate
conditions. By using two forms of a primer that are allele specific only at the
terminal 3'-nucleotide in a PCR, a limited number of results are possible. The
‘normal’ form of the primer is refractory to PCR on mutated DNA and
conversely, the ‘mutated’ form of primer is refractory to PCR on ‘normal’
DNA. In this way, the requirement for complex post-amplification procedures
is eliminated.

This technique has recently been modified so as to allow simultaneous
fluorescent [F] detection of the factor V Leiden and the prothrombin
3'-untranslated region (G20210) mutations by Maher et d. (1999).
Fluorescent-labelled oligonucleotide primers are incorporated into the PCR
reaction mixture and the resulting amplicons are visualised by fluorescence
spectroscopy in an ABI Prism™ 310 genetic analyser.
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Section 2

Materials and Methods

Section 2 addresses both the materials and methods used to generate data for this
project. Divided into two parts, part 1 outlines all samples, reagents and equipment
utilised. Part 2 is a detailed description of the laboratory procedures employed to
establish the experimental data.

2.1

Materials

2.1.1

Blood Samples
Two sets of 68 blood samples were obtained.
The first set (Test set) was taken from patients attending the Royal Brompton
and Harefield N.H.S. Trust, Harefield Hospital, Middlesex, U.K. These
patients were selected on the basis that they were either known or highly likely
to have cancer in the thoracic region. These samples were obtained preoperatively by venipuncture with fully informed patient consent.

The second set (Control set) was also taken from patients attending the Royal
Brompton and Harefield N.H.S. Trust, Harefield Hospital, Middlesex, U.K.
The criteria for patient selection in this case was that they were not known to
have cancer. These samples were age- and sex- matched with the test set of
samples. Blood samples were obtained by venipuncture and collected in
trisodium citrate-containing vacutainer tubes.

2.1.2

Materials used for the Phenotypic Assessment of Prothrombotic
Tendency

The materials used for phenotypic assessment of prothrombotic tendency
included the Thromboelastograph® Coagulation Analyzer (TEG™), metal
collars and stabs, plastic cups and pins, stripper tool.

All materials for thromboelastographic analysis were supplied by:
Haemoscope Corporation,
7855 Gross Point Road, Suite G-4,
Skokie, Illinois 60077, USA.
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2.1.3

Materials used for the Genotypic Assessment of Prothrombotic Tendency
2.1.3.1 Control DNA samples
Homozygous and heterozygous DNA samples containing the
methylenetetrahydrofolate reductase (MTHFR) C677T mutation were
supplied from Dr. Henk J. Blom (Department of Paediatrics,
University Hospital Nijmegen, Nijmegen, The Netherlands).

Homozygous and heterozygous DNA samples for the Factor V Leiden
mutation were obtained from Dr. Andreas Hillarp (Department of
Clinical Chemistry, Lund University Hospital, Malmo, Sweden).
2.1.3.2 DNA extraction from whole blood
DNA was extracted from either the buffy coat or concentrated red cell
moiety of centrifuged whole blood samples using a QIAamp Blood Kit
(Qiagen Ltd., West Sussex, UK).
The kit is supplied with spin columns, 2 ml collection tubes, reagents
including Qiagen protease, solutions ALl and AL2, and buffers AW
and AE.

For best results, the following steps were taken in accordance with
manufacturer’s instructions prior to using the kit. The lyophilised
Qiagen protease was reconstituted with sterile dH20, aliquots were
made and stored at -20°C. Buffer AL was prepared by adding the
contents of solution ALl to solution AL2, mixing well and storing in
the dark at room temperature. Ethanol (96-100%) was added to buffer
AW as directed.
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2.1.3.3 Reagents used for PCR

PCR buffers:

1 Buffer
i
!

Relevant PCR reaction

Composition

Buffer 1:

Factor V Leiden

540 mM Tris-HCl (pH 8.8)

A Gitschier PCR buffer

Factor Xllla Val34Leu

54 mM MgCb

designated 1 OX was

Protein C (TATA box)

54 pM EDTA

prepared.

Antithrombin Ill

133 mM (NH4)2S04

1

I

(adaptedfrom Bertina ei gl.,
1994)
Buffer 2:

MTHFR C677T

100 mM Tris-HCl (pH 8.3)

A PCR buffer designated

500 mM KCl

1 OX was prepared

15mM MgCb
(adaptedfrom Frosst ei ql.,
1995)

Table 2.1:

The two types of PCR buffers that were used in this projeet. The
partieular PCR reaetions for whieh they were used and their respective
compositions are shown.
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Auxiliary Reagents (all of Analar grade) used in PCR reactions:

1

Reagent

Supplier

Working

Storage

Final

Stock

Conditions

Concentration

Concentration
DMSO

Sigma (Sigma,

(Dimethylsulphoxide)

Poole, U.K.)

100%

in PCR
Stored at

8%

room
temperature

BSA

Sigma (Sigma,

4 mg/ml

Stored in

(Bovine Serum Albumin)

Poole, U.K.)

Designated

Aliquots of

lOX

1 OX BSA

0.4 mg/ml

at -20°C
B-Mercaptoethanol

BDH Chemicals

200 mM

In the dark

Ltd. (BDH

Designated

at room

Chemicals Ltd.,

25X

temperature

5U/pl

Stored at

2 U or 1 U

-20°C

(i.e. 0.4 or 0.2 pi

8 mM

Poole, U.K.)
Tag DNA polymerase

Promega
(Promega,
Madison, WI)

Triton X-100

Gelatine

Tag stock)

Sigma (Sigma,

1 g/100 ml

Stored at

Poole, U.K.)

Designated

room

lOX

temperature

Oxoid Ltd.,

1 mg/ml

Stored at

(Oxoid Ltd.

Designated

room

London SEl.)

lOX

temperature

1 mg/ml

100 pg/ml

used in the PCRs in
the project.

dNTP mixtures:

Individual deoxynucleoside triphosphates (dATP, dTTP, dGTP and
dCTP) were supplied by Promega (Promega, Madison, WI) at a
concentration of 100 mM each. A working stock dNTP mix of

45

concentration 1.2 mM for each dNTP was prepared by adding 2.5 pi of
each dNTP to 190 pi of sterile dH20. Stock dNTPs and working stock
dNTP mix were stored at -20°C.

Primers for PCR and SDM-PCR

All blood samples were analysed with the aid of PCR as it greatly
enhances the mutation detection systems that were subsequently used.
To do this, primer sets (forward and reverse primer) were selected
which flanked specific regions in the relevant genes known to possess
the mutations of interest. Table 2.3 provides an overview of all
relevant primer details.

Oligonucleotide primers were synthesised, purified by HPLC and
supplied in (a) lyophilised form or (b) reconstituted in 1 ml of sterile
dH20 by Oswel (Oswel, Abingdon, U.K.)

Primer concentrations were calculated using data provided by Oswel as
follows:
Cone, of primer (/^ol/ml)=

quantity (/^/ml)
molecular weight of primer (/^)

Working stocks for individual primers were prepared to contain
10 pmol/ pi of primer. Small aliquots of stock primer were prepared in
1.5 ml eppendorf tubes and stored at -20°C.
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Sterile Water:
Distilled H2O (dH20) was sterilised by autoclaving at 121 °C for 15
mm.

2.1.3.4 PCR Product Purification:
All amplicons from PCRs were purified of possible interfering
substances using a QIAquick PCR purification kit (Qiagen Ltd., West
Sussex, U.K.). The kit is supplied with QIAquick spin columns, 2 ml
collection tubes, and buffers designated buffer PB and buffer PE.
Ethanol (96-100%) must be added to buffer PE prior to use.

2.1.3.5 Restriction Enzymes used for RFLP analysis
Various restriction enzymes were used to determine the presence of
polymorphisms within different amplicons. The relevant enzymes and
associated buffers were supplied by Roche (Roche Diagnostics Ltd.,
East Sussex, UK.) and are detailed in table 2.4. All were stored at
-20°C.

Enzyme

Recognition

SuRE/CuHM Buffer

Sequence

Volume activity
(units/ pi)

Hinfl

gi ANTC

H

10

Hind III

Aj AgCTT

B

10

Dra I

TTTi AAA

M

10

Bgll

Aj GATCT

M

10

buffers.

2.1.3.6 Agarose Gel Electrophoresis:
Electrophoresis Apparatus:
Two types were used
(i)

Horizon® 58 horizontal gel apparatus (for large gels)
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(ii)

Horizon® 11.14 horizontal gel apparatus (for small gels)
both from Life Technologies Inc. (Rockville, U.S.A.).

Agarose:
Ultra Pure Agarose electrophoresis grade was obtained from (Life
Technologies Inc., Rockville, USA)

Ethidium Bromide:
Ethidium Bromide (EtBr) was supplied by Sigma (Sigma, Poole,
U.K.). A working stock of 10 mg/ml was prepared in sterile dH20 and
was stored in the dark at room temperature.

Agarose Gel Electrophoresis Buffers:
A stock lOX Tris-Acetate-EDTA (lOX TAE) buffer was prepared:
400 mM Tris [pH 7.8]
400 mM glacial acetic acid
20 mM EDTA

From the stock lOX TAE buffer, a IX working concentration was used
for the preparation of agarose gels and for use as electrophoresis
running buffer. 1X TAE buffer was also modified by the addition of
ethidium bromide.

Non denaturing Loading Buffer:
6.6 ml glycerol
3.3 ml lOX TAE
10% (w/v) bromophenol blue

Molecular Weight Markers:
Roche (Roche Diagnostics Ltd., East Sussex, U.K.) supplied Grade V
molecular weight markers. These markers were generated by digesting
pBR322 to completion with the restriction enzyme Hae III to yield 22
DNA fragments ranging in size from 8-587 bp in length.
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2.1.3.7 Polyacrylamide Gel Electrophoresis and SSCP analysis
2.1.3.7(a)

Electrophoresis Apparatus:
Electrophoresis was performed using yertical gels
assembled on the Horizon® 11.14 gel apparatus
( Life Technologies Inc., Rockyille, U.S.A.).

2.1.3.7(b)

Polyacrylamide gels:
50 ml of 12% (w/y) Tris Glycine Resolying gel for
SSCP analysis was prepared as follows:

Reagent

Volume (ml)

H2O

16.50

30% (w/y) acrylamide mix

20.00

1.5 M Tris (pH 8.8)

12.50

10% (w/y) SDS

0.50

10% (w/y) Ammonium persulphate

0.50

TEMED

0.02

Table 2.5:

Reagents required for preparing resolying gel.

10 ml of Tris Glycine Stacking gel was prepared as
follows:
Reagent

Volume (ml)

H2O

6.80

30% (w/y) acrylamide mix

1.70

1.5MTris (pH 8.8)

1.25

10% (w/y) SDS

0.10

10% (w/y) Ammonium persulphate

0.10

TEMED

0.01

Table 2.6:

Reagents required for preparing stacking gel.

Note: 10% (w/v) Ammonium persulphate and 30% (W/y)
acrylamide mix were preparedfreshly each week.
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2.1.3.7(c)

Denaturing Dye for SSCP analysis:
95% (v/v) formamide
lOmM EDTA (pH 8)
0.1% (w/v) Bromophenol Blue

(d)

Electrophoresis buffer:
A 5X Tris Glycine Stock was prepared.
15.1 g Tris
94.0 g Glycine
.. .made up to 1 Litre with sterile dH20.

A 0.5X Tris Glycine solution was used for
electrophoresis runs.

(e)

Solutions for Silver Staining:
Fixing Solution:

450 ml dH20
50 ml Ethanol
2.5 ml Glacial acetic acid

Staining Solution:

0.5 g Silver Nitrate
500 ml dH20

Developing Solution: 0.095 g Sodium Borohydride
30 g NaOH
3 ml 40% (v/v) Formaldehyde
made up to 1 litre with dH20

2.1.3.8 Cloning DNA fragments of interest.
The Original TA cloning® Kit (Invitrogen BV, The Netherlands) was
used for cloning DNA fragments of interest.
The kit is supplied in two boxes designated ‘modules’:
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(a)

Module 1: The TA Clonirm® reagents are comprised of:
Linearised pCR 2.1® (25 ng/pl) vector in 10 mM Tris-HCl (pH 7.5),
1 mM EDTA. lOX ligation buffer: 60 mM Tris-HCl (pH 7.5), 60
mM MgCb, 50 mM NaCl, 1 mg/ml bovine serum albumin, 70 mM Bmercaptoethanol, 1 mM ATP, 20 mM dithiothreitol, 10 mM
spermidine. T4 DNA Ligase: 4.0 Weiss units/pl. Sterile Water:
Deionised, autoclaved. Appropriate reagents required for the
amplification of a control segment of DNA to be ligated into the vector
(e.g. lOX PCR buffer, 100 mM dNTPs, control DNA template)

(b)

Module 2: The One ShoH^ Competent Cells comprised of:
SOC medium containing 2% (w/w) tryptone, 0.5% (w/w) yeast
extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgS04, 20 mM glucose
(dextrose). B-mercaptoethanol (0.5 M). INVa F’ super competent
^ coli cells (Genotype: F’ endAl recAl hsdR17 (rC, nik^) supE44thi-1
gvrA96 erlAl OSOlacZAM 15(lacZYA-argF)U 1699'). Supercoiled
transformation control plasmid - pUC18

TA Cloning® reagents (Module 1) were stored at -20°C
One Shot™ Competent Cells (Module 2) were stored at -80°C.

Additional Reagents required for Cloning but not provided by the
Original TA Cloning® Kit:
X-Gal stock solution: 40 mg/ml 5-bromo-4-chloro-3-indolyl-B-Dgalactoside (X-Gal) in DMF.

Luria-Bertani (LB) agar plates containing 1% (w/w) tryptone, 0.5%
(w/w) yeast extract, 1% (w/w) NaCl, 15 g/1 agar (pH 7). Ampicillin
(50 pg/ml) and X-Gal stock (40 mg/ml) were added to the cooled
autoclaved agar before the plates were poured.
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2.1.3.9 Quick screen for plasmids with insert:
Buffer 1:

0.2 N NaOH, 1% (w/v) SDS.
(freshly prepared and stored at room temperature)

Buffer 2:

3 M potassium acetate, 1.8 M formic acid.
(made in advance and stored at room temperature)

Lysis Buffer Lysis buffer was comprised of the following
combination of reagents;
9 volumes of 2.5% (w/v) bromophenol blue, 0.25%
(w/v) xylene cyanol, 25% (w/v) Ficoll type 400 (made
in advance and stored at room temperature) : 11
volumes of sterile distilled water : 40 volumes of
buffer 1 above.
2.1.3.10 LB Broth:
LB broths were required for culture of positive clones.
One hundred ml broth was prepared and aliquoted into 5 ml volumes
and these were then autoclaved at 12rC for 15 minutes.
2.1.3.11 Isolation of plasmids from cells:
Wizard® Plus SV Minipreps DNA Purification System (Promega,
Madison, WI, USA) was used in accordance with manufacturer’s
instructions.
This kit enables the isolation of plasmids from bacterial cultures
ranging from 1-10 ml nutrient broths.

Contents of the kit include:
Cell Resuspension Solution: (50 mM Tris-HCl (pH 7.5), 10
mM EDTA, 100 pg/1 Rnase A.), Cell Lysis Solution: (0.2 M NaOH,
1%SDS), Neutralisation Solution: (4.09 M guanidine
hydrochloride, 0.76 M potassium acetate, 2.12 M glacial acetic acid
(pH 4.2)), Column Wash Solution: (95% (v/v) ethanol must be
added as directed.) final concentrations: 60 mM potassium acetate, 10
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mM Tris-HCl (pH 7.5), 60% ethanol, Miniprep spin columns,
Collection tubes, Alkaline protease solution. Nuclease-free water
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2.2

Methods

2.2.1

Thromboelastograph Procedure

Blood samples were obtained using a sterile needle. Following venipuncture, 10 ml
of blood was drawn gently into a sterile disposable polypropylene syringe. 5 ml was
aliquoted into an appropriate vacutainer containing sodium citrate anticoagulant to be
used later for genomic analysis (see Section 2.2.2). The remaining blood was for use
in the TEG.

2.2.1.1 Preparation of the Thromboelastograph Coagulation analyser for use with
disposable cups and pins
A box containing disposable cups and pins for use with the TEG was placed
on a flat surface with the printed side up and the inner styrofoam was partially
moved to expose the cups and rows of pins. Touching the plastic pins and
cups by hands or gloves was avoided at all times.

2.2.1.2 Pin assembly (see Figure 2.1):
a)

A metal stab was grasped by the (top) pointed end. The flat edge of
the stab was aligned with the matching hole on the exposed wings of
the pins.

b)

The stab was firmly inserted into the pin and the pin was then removed
from the Styrofoam bed and placed directly into a plastic cup.

Both the cup and the pin were placed into the metal collar of a selected
channel on the TEG instrument. The stab was pressed down firmly to fully
seat both the stab in the pin and the cup in the collar. The metal edges of the
stab and collar should be tight against the plastic edges, respectively. The stab
was then placed in the ‘ UP ’ position on the TEG instrument. The cup and pin
were allowed to warm to 37°C for ten minutes.
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At this point, 200 pi of whole blood sample was pipetted into the plastic cup
within 4 minutes of taking the blood sample.

Using the turning screw, the metal stab (with plastic pin now attached) was
depressed into the cup containing the blood sample. A layer of mineral oil
was carefully placed over the blood sample in the cup using a syringe and the
TEG channel was then activated by pressing the “RUN” button for the
selected channel of the instrument. Sample identification data was entered
into the computer terminal using system software.

2.2.1.3 During the TEG run
A thromboelastographic tracing illustrating the coagulation characteristics of
the blood sample appeared on the visual display unit as time elapsed (i.e. the
trace formed at a rate of 2 mm/'min.). Numerical data values were also shown
for the measured clotting parameters (0, MA, k ^ Section 1.6).

2.2.1.4 Ending the TEG run
When the TEG tracing was complete, the column was raised to the uppermost
position using the turning screw. The metal collar of the stab was pulled
straight down to remove from the column. In order to remove the plastic pin
from the stab, the pin assembly was held by the metal stem (pointed end) of
the stab. The notched edge of the stripper tool was placed around the metal
collar of the stab so that the sharp edges of the stripper tool inserted between
the metal and plastic wings of the pin. The stripper tool was closed slowly and
the plastic pin dislodged and carefully discarded into a biohazard container.

The metal pin was reinserted into the TEG for the next use. Using the stripper
tool, the plastic cup was removed from the metal collar by placing it opened
wide under the collar and levering the cup off and disposing it safely into a
biohazard container.

56

WETAL STA8

PLASTIC

PIN

plastic

cup

METAL

COLLAR
HfR'TiNfGr

metal collar.

BLOCK

MOh>£x

Figure 2.1: The TEG pin assembly.
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2.2.2

DNA extraction from whole blood samples

2.2.2.1 Preparation of buffV coat
Whole blood samples were centrifuged at 2000 rpm at room
temperature for 10 minutes to achieve three fractions:
a)

Plasma (the top layer)

b)

Huffy coat (the thin intermediate layer)

c)

Red cell concentrate (the bottom layer)

Supernatent plasma was removed using a Pastuer pipette to allow easy
access to the buffy layer.

22.2.2

DNA extraction procedure
DNA was extracted from the leucocyte-rich buffy coat using the
QIAamp blood kit (Qiagen Ltd., West Sussex, UK). Extraction
involved the following steps as recommended by the manufacturer:

•

In a 1.5 ml eppendorf tube, 20 pi of Qiagen protease and 200 pi of
buffer AL were added to 200 pi of buffy coat. Thorough mixing was
achieved by vortexing for 15 seconds.

•

The mix was incubated for 10 minutes at 70°C for complete lysis of
leucocytes.

•

Subsequently, 210 pi of ethanol (96-100%) was added and the lysate
was then placed into a QIAamp spin column positioned over a
collection tube.

•

DNA was bound to the silica gel membrane of the spin column by
centrifugation at 8000 rpm for 1 minute.

•

The spin column was washed twice with 500 pi of buffer AW
(replacing the collection tube each time) and the DNA was eluted with
200 pi of preheated sterile dH20 (70°C) into a sterile 1.5 ml eppendorf
tube)

•

The yield of DNA extracted was determined spectrophotometrically by
measuring the absorbance of the eluate at 260 nm. Purity of the
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extracted DNA was determined by measuring absorbances at 260 nm
and 280 nm, whereby pure DNA has an A260/280 ratio of 1.7-1.9.

2.2.3

PCR and SDM-PCR

2.2.3.1 Amplification process
A series of reaction mixes were prepared prior to amplifying
gene fragments by PCR. The components of each mix for all
PCRs carried out have been presented in tabular form for
clarity (see Table 2.7 for a complete listing of reaction
components).
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The thermal cycling conditions for all reactions except the
amplification of the MTHFR gene fragment were as follows:

Initial Denature

94°C for 5 min.

1 cycle

Denature

94°C for 1 min.

Anneal*

58°C for 1 min.

Extend

72°C for 1 min.

Final Extension

72°C for 7 min.

1 cycle

rC

Holding

30 cycles

* Annealing temperature was adjusted for particular
reactions i.e.
Reaction

Annealing Temperature:

Protein C TATA

60°C

Antithrombin III, Factor V

58°C

Factor XIII

55T

As illustrated in Table 2.7, amplification of the MTHFR 198 bp
fragment involved a different array of reactants. In addition,
the thermal cycling profiles also varied from those used above
and were as follows:

Initial Denature

96°C for 5 min.

1 cycle

Denature

93°C for 50 sec.

Anneal

55°C for 50 sec.

Extend

72°C for 30 sec.

Final Extension

72°C for 7 min.

1 cycle

4T

Hold

35 cycles
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All amplification reactions were performed using a PTC-150
minicycler (MJ Research Inc., Watertown, MA). This thermal cycler
possessed a heated lid that obviated the need for a mineral oil layer to
be placed over reaction mixes. In each case the final reaction volume
ranged between 50-100 pi contained in thin-walled 200 pi reaction
tubes (see Figure 2.2).

Figure 2.2:

Loading the PTC-150 minicycler with PCR reaction
tubes in the laboratory.

All amplified fragments were analysed on 1.5% (w/v) agarose gels in
conjunction with Grade V molecular weight markers.

2.2.4

Agarose gel electrophoresis

Depending on the resolution required, either a 1.5% (w/v) or a 3% (w/v)
agarose gel (Life Technologies Inc., Rockville, USA) was used. Agarose
was solubilised in each case in IX TAE containing 35 ng/ml Ethidium
Bromide (EtBr).
Electrophoresis was performed for 1-2 hours at 90V.
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Figure 2.3:

Loading a horizontal agarose gel with PCR product
mixed with a non-denaturing loading dye. Note how
the blue dye facilitates visualisation of sample.

Gels stained with EtBr were visualised on an ultraviolet transilluminator.
Images were analysed and stored using the GRAB-IT'^'^ software of
UVPs Gel Documentation and Analysis system-GDSSOOO (Ultra-Violet
Products Ltd., Cambridge, UK).
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2.2.5

PCR product purification

For efficient restriction enzyme digestion, it was essential that amplicons
obtained by PCR or SDM-PCR were purified to remove all traces of
primers, salts, excess nucleotides and polymerases. This purification
process was achieved by utilising the QIAquick PCR purification kit
(Qiagen Ltd., West Sussex, UK) as directed by the manufacturer.
•

Five volumes of buffer PB were added to one volume of PCR product
and the mixture was then applied to a QIAquick spin column that was
positioned in a collection tube.

•

Double stranded DNA was bound to the silica gel membrane of the
column by centrifugation at 8000 rpm for 60 sec.

•

Bound DNA was washed by the addition of 750 pi of buffer PE to the
column and centrifugation at 8000 rpm for 60 sec.

•

Purified DNA was eluted from the column with 30 pi sterile dH20
(preheated to 70°C) into a sterile eppendorf tube.

•

Purified PCR products were stored at -20°C until required for
subsequent post amplification analysis.

2.2.6

Restriction Endonuclease Digestion of Amplified Fragments

Following PCR (or SDM-PCR) the presence of mutations in amplified
DNA fragments was determined using Restriction Enzyme analysis.
Restriction sites are created by the presence of specific mutations and
these governed the type of restriction enzyme that was used.

The relevant enzymes used are detailed in Table 2.4. In general, the
digestion protocol used was as follows:
PCR Purification Product*

22.5 pi

Appropriate SuRE/Cut^'^ 1 OX buffer

2.5 pi

Restriction Enzyme

1 pi
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* A control digest was also prepared for eaeh enzyme using 1 pi of DNA
(0.25 pg). The final reaction volume was 50 pi. All tubes were incubated
at 37°C in a water bath for 1.5 h (4 h for MTHFR mutation) and samples
were analysed by electrophoresis in a 1.5% agarose gel (3% agarose gel
for MTHFR mutation)

2.2.7

Single Stranded Conformational Polymorphism (SSCP) Analysis for the
Identification of the FXIII Val34Leu Mutation

The genotype of Factor XIII was determined by PCR amplification as
described followed by SSCP analysis. The SSCP technique used in this
project was optimised and involved the following:

•

Equal volumes (15 pi each) of purified PCR product and denaturating
buffer were mixed in 200 pi thin walled eppendorf tubes.

•

Denaturation for SSCP analysis was performed using the PTC-150
minicycler (MJ Research Inc., Watertown, MA). An initial step of 96°C
for 5 minutes was followed by a holding step keeping the tubes at 80°C
until just prior to loading the 12% (w/v) polyaerylamide gel.

•

Denatured samples were applied to the wells of the polyacrylamide gel
stacking layer using a sterile needle and syringe (Figure 2.4 (a)).

•

Electrophoresis was carried out at room temperature for 16 h at 65 V and
constant current of 15 amps in a 0.5X Tris-Glycine electrophoresis buffer
(Figure 2.4 (b)).

•

The gel was carefully removed from the electrophoresis apparatus and its
orientation noted by cutting a small fragment from the bottom left-hand
corner of the gel.

•

Silver staining of the gel consisted of three stages (Figure 2.4 (c)).
i)

Fixing for 20 minutes in Fixing solution.

ii)

Staining for 2 h in Silver Nitrate (1 g/1) Staining solution.

iii)

Developing for up to 30 minutes in Developing solution.

65

•

Mobility shift of single-stranded DNA was visualised and any potential
mutations were confirmed later by DNA sequence analysis (see Section

2.2.10).

Figure 2.4 (a): Loading a vertical Polyacrylamide gel with
samples for SSCP analysis.
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Fiuure 2.4 (b): Photograph showing the Polyacrylamide Gel apparatus
during an electrophoretic run. On the left are the
solutions required for subsequent silver staining.

Figure 2.4 (c): Silver staining a polyacrylamide gel in the laboratory.
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2.2.8

Cloning of Cells
Ligation of the 183 bp PCR insert (from the Factor XIII gene) with the
pCR 2.1 vector and subsequent transformation of the vector into One Shof^*^
FNVaF’ Competent Cells was performed using the Original TA Cloning® Kit
(Invitrogen , Groningen, The Netherlands) in accordance with manufacturer’s
instructions.

2.2.8.1

Procedure for cloning into pCR 2.1 competent cells:
(a)

LIGATION:

The optim.um amount of PCR product required to ligate with 50 ng of
pCR 2.1 vector was first calculated using the following formula as
given in kit instructions:

^ „ „„
,
(Y bp PCR productX50 ng pCR ® 2.1 vector)
X ng PCR product = A— ------- ---------^
^ ^/
(size in bp of the pCR®2.1 vector :« 3900)

For example, with respect to the 183 bp Factor XIII fragment of
interest in this project the values substituted were as follows:

1

X ng PCR product =

(l83bpX50ng)

. ._

—= 2.35 ng
{3900bp)

—7

Using the appropriate volume (pi) containing this amount of fresh (<1
day old) PCR product, the ligation reaction was set up by adding
1 pi 1 OX ligation buffer, 2 pi pCR® 2.1 vector (25 ng/pl), and sterile
water to a total volume of 9 pi. Finally 1 pi of T4 DNA Ligase
(4.0 Weiss units) was added. The ligation reaction was incubated at
14°C overnight.
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(b)

TRANSFORMATION:
When using INVaF’ cells it was recommended that Luria-Bertani (LB)
plates containing 50 pg/ml of ampicillin were prepared in advance.
Using aseptic technique, the surface of the plates were then spread with
40 pi of 40 pg/ml of X-Gal and allowed to soak into the plates.

Two pi of 0.5 M p-mercaptoethanol was pipetted into each vial of the
competent cells and mixed gently. Two pi of each ligation reaction
was pipetted directly into the competent cells and again mixed gently.
Heat shock of these cells was achieved by incubating in a 42°C
waterbath for exactly 30 seconds. Vials were removed and placed on
ice for 2 minutes.

Two hundred and fifty pi of SOC medium (that had been thawed at
room temperature) was added to each vial. On two separate LB agar
plates containing 50 pg/ml of ampicillin and 40 pg/ml of X-Gal, 50 pi
and 200 pi from each transformation vial was spread using aseptic
technique. Plates were inverted and incubated for at least 18 h in a
37°C incubator.

2.2.8.2 Blue White Screening
Blue-white screening for the presence of recombinant plasmids on each
transformation plate was carried out. P—Galactosidase is an enzyme
that can hydrolyse the synthetic chromogenic substrate 5-bromo-4chloro-3-indolyl-p-D-galactopyranoside (X-Gal) to yield a blue
product. Insertional inactivation of the lacZ gene (which encodes Pgalactosidase) in the production of a recombinant plasmid would
prevent the development of the blue colour. Blue colonies are not
likely to contain religated vector. White colonies lack the expressed
P—galactosidase and are therefore likely to contain religated vector.
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Figure 2.5:

A representation of an Ampicillin/IPTG/X-Gal plate; there is an
absenee of P-galactosidase activity as a result of insertional
inactivation of the lacZ gene in white colonies and these,
therefore, are likely to contain recombinant plasmids.

2.2.8.3 Rapid Colony Screening Procedure (Le Gouill and Derv, 1991)
Genuine uptake of insert within plasmids as suggested by the presence
of white colonies on LB agar plates was screened for using the
following procedure. Selected white colonies were gently picked up
using a sterile P20 pipette tip. The tip was touched very lightly on the
surface of a fresh LB agar plate to form a reference grid template. The
remainder of the colony in the tip was transferred into an eppendorf
tube that contained 16 pi (large colonies, 1.5 mm) or 8 pi (small
colonies < 1.5 mm) of Lysis buffer. The colony was resuspended
avoiding the formation of bubbles. Following this, 3 pi (or 1.5 pi for
small colonies) of buffer 2 was aliquoted on to the wall of the tube and
the tube spun for 4 minutes. The supernatent was used for analysis by
electrophoresis on a 0.8% (w/v) agarose gel. Potential recombinants
were identified by comparing electrophoretic patterns of plasmids
purified from blue and white colonies.

Cultures of the selected positive clones were then prepared.
Using a sterile loop 5 ml of LB broth (containing 50 pg/ml ampicillin)
in a culture bottle was inoculated with a clone. Bottles were incubated
in a shaking waterbath overnight at 37°C in a slanted position. The
cells from these cultures were harvested for plasmid DNA purification.
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2.2.9

Plasmid Isolation and Purification

2.2.9.1 Isolation
Following the overnight incubation, a pellet of cells was obtained by
centrifugation at 10,000 rpm for 10 minutes. The supernatent was
poured off and any excess media removed by blotting the tube on a
paper towel.

Using the Wizard® Plus SV Minipreps DNA Purification System kit,
the pellet of cells was resuspended in 300 pi of Cell Resuspension
Solution and then transferred to a 1.5 ml microcentrifuge tube.

Three hundred pi of Cell Lysis Solution was added and mixed by
inverting the tube 4 times thereby rendering the suspension clear in
appearance.

Three hundred pi of Neutralization solution was added and again
mixed by inverting the tube several times.

The lysate was centrifuged at 10,000 rpm in a microcentrifuge for 5
minutes until a pellet had formed.

2.2.9.2 Purification
For each miniprep, one Wizard™ Minicolumn was prepared as
follows: The plunger from a 3 ml disposable syringe \^as removed and
the syringe barrel was attached to the Luer-Lok extension of the
Minicolumn. One ml of the resuspended resin was then delivered into
the barrel.

All of the cleared lysate was carefully removed from each miniprep
and transferred into the barrel of the Minicolumn/Syringe assembly
containing the resin.
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The syringe plunger was carefully re-inserted into the syringe barrel
and used to gently push the slurry into the minicolumn.

The syringe was detached from the Minicolumn and the plunger was
removed from the syringe barrel again. Two ml of Column Wash
Solution (after the addition of ethanol) was then pipetted into the barrel
of the Minicolumn/Syringe assembly. The plunger was re-inserted into
the syringe barrel and the Column Wash Solution was gently pushed
through the Minicolumn.

The syringe was removed and the Minicolumn was transferred to a
1.5 ml microcentrifuge tube that was then centrifuged at 10,000 rpm
for 2 minutes to dry the resin.

The Minicolumn was then transferred to a new 1.5 ml microcentrifuge
tube and 50 pi of sterile dHiO was added to the Minicolumn. To elute
the DNA, a centrifugation step at 10,000 rpm for 20 seconds was
performed. Upon completion, the Minicolumn was removed and
discarded and the plasmid DNA was stored in the microcentrifuge tube
at rC or -20T.
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2.2.10 Preparation of plasmid for Sequencing
2.2.10.1

Restriction Digest
Purified plasmid was digested with the restriction enzyme EcoRI at
37°C for 1.5 hrs and then analysed on a 1.5% (w/v) agarose gel for
the presence of a 183 bp insert.

2.2.10.2 DNA Sequencing
DNA was sequenced using a CEQtm 2000 DNA Analysis System
(Beckman Coulter Inc., California, USA). Based on the dideoxy
chain termination sequencing methodology first described by Sanger
in 1976, dideoxy-terminator cycle sequencing was performed as
recommended by Beckman Coulter using the CEQ dye-labelled
Dideoxy-Terminator Cycle Sequencing Kit (Galvin ct d. 1998).
Dideoexy-terminated fragments were separated and analysed on the
CEQ 2000 DNA Analysis System (see Figure 2.6).
Project: Default

System : CEQ 2000 DNA Analysis System

Sample : 62 M13F.F09_99102209CF
Result :62M13F.F09 99102216FY

Analysis System (Beckman Coulter Inc., California, USA).
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2.2.11 Bio-informatics
The Internet
The internet was of immense importance in this project. It provided access to
a vast amount of information from a multitude of resources or databases. Its
main disadvantage was the time needed to sift through much of the
information on the World Wide Web (WWW) that was not of an adequate
standard for professional medical research purposes (Whyte, 1999).

The following table outlines the internet addresses, known as URLs (Uniform
Resource Locaters), of database resources used in the collection of data
(Nierlich et al., 1999). Simply mouse-clicking on ‘hypertext links’ embedded
in these web pages or ‘sites’ allowed navigation to other sites of interest.

URLs (Uniform Resource Locators)

Service/Database

http://www.ncbi.nlm.nih.gov/

GenBank is a database of all publicly available
nucleotide and protein sequences, including
supporting bibliographic and biological information.
Established in 1982 by the US National Institutes of
Health (NIH), has been based at the National Center
for Biotechnology Information (NCBl) since 1992 a division of the National Library of Medicine
(NLM).

http://www.ncbi.nlm.nih.gov/BLAST/

NCBl BLAST (Basic Local Alignment Search Tool)
allows protein and DNA homology searches.

http://www.ncbi.nlm.nih.gov/Entrez/

NCBl Entrez allows retrieval of molecular biology
data and bibliographic citations from the NCBTs
integrated databases.

http://www.ncbi.nlm.nih.gov/PubMed/

NCBl PubMed is a bibliographic database containing
citations for nearly 9 million biomedical articles from
the National Library of Medicine’s MEDLINE and
pre-MEDLlNE databases.

http://www.ncbi.nlm.nih.gov/OMIM/

NCBl OMIM (On-Line Mendelian Inheritance of
Man) database is a comprehensive catalog of human
genes and diseases.

http://www.hbuk.co.uk/Jmb

Journal of Molecular Biology
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URLs (Uniform Resource Locators)

Service/Database

http://www.golgi.harvard.edu/

Biology and Molecular Biology (Harvard)

http://www.pasteur.fr/other/biology/english/rubriques-uk.html

Molecular Biology (Pasteur Institute)

http://www.expasy.hcuge.ch/

Molecular Biology and Biochemistry (Expasy, U.
Geneva)

http://www.healthgate.com

Free Medline Literature database

http: //WWW. who. i nt/

World Health Organisation

http://www. indigo. ie/~amls

Academy of Medical Laboratory Science home page

http://www.cit.ie

Cork Institute of Technology home page

http://www.ucc.ie/faculties/medical

UCC Medical Faculties home page

Table 2.8:

Relevant World Wide Web ‘sites’ (URLs) and their respective
services/databases that they provide.

Sequencher'^^

Sequencher™ (Gene Codes Corporation, Ann Arbor, MI, USA) is a DNA
sequencing tool written for the Macintosh® family of desktop computers. The
software was used to analyse data obtained from DNA sequencing of the
183 bp FXIII A-subunit (see Section 2.2.10.2). Integrated analysis features of
Sequencher^”^ enabled Open Reading Frames, protein translations, and
restriction maps to be determined quickly and accurately for particular
sequences.

Submitting Data to a Public Database

Following the determination of a novel polymorphism (see Section 3), relevant
sequence data was made available to the scientific community by submitting it
to a public sequence database. The International Collaboration of Nucleotide
Sequence Databases is composed of three partners: GenBank, EMBL
(European Molecular Biology Laboratory) and DDBJ (DNA Database of
Japan). Data submissions are exchanged between all three partners.
Therefore, it is necessary to submit to just one of these locations (Baxevanis et
ai, 1997).

Electronic mail (E-mail) was used to send a formatted message containing
sequence data to the GenBank database at the following URL:
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http://www.ncbi.nlm.nih.gov/Banklt/
An accession number is a unique identifier for a particular sequence and was
assigned by GenBank to the submitted sequence. This number is of a
two-letter, six-digit format and is a pre-requisite in many journals as proof of
submission as a condition of publication. Knowledge of the accession number
facilitates the retrieval of the sequence and associated annotation fi'om
databases.
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Section 3

Results and Discussion

3. Results and Discussion

Venous thrombosis and its feared complication pulmonary embolism account
for a significant number of hospital admissions and deaths annually (Lowe et
al., 1992; Ens et al., 1995; Verstraete, 1997). Several risk factors, that may be
familial or acquired, have been associated with increased predisposition to
thrombosis (Schwartz et al., 1988; Davidson et al., 1990; Ens et al., 1995;
Green et al., 1996; Verstraete et al., 1997). Some of these include increased
age, surgical trauma, malignancy, prolonged immobility and a number of
mutations in genes that code for proteins involved in blood coagulation. In
this study, a total of sixty-eight Test subjects suspected with cancer were
selected for functional and genomic assessment of their prothrombotic
tendency. Blood samples were collected from patients attending the Royal
Brompton and Harefield NHS I'rust, Harefield Hospital, (Middlesex, U.K.).
Fifty-four of these were from males and fourteen were females. Test subjects
ranged in age from their third to ninth decades with the majority being older
than fifty years of age. A second set of sixty-eight blood samples was also
collected for use as a Control group. This was a randomised age-and sexmatched group of subjects attending the same hospital with no history of
thrombotic or cancer-related disease. All of these features are summarised in
Tables 3.7 and 3.8. Participation in this project required prior ethical approval
and consent. Both were obtained at Harefield Hospital.

Genomic assessment ofprothrombotic tendency.

High quality genomic DNA was purified from all Test and Control subjects.
The integrity of the template DNA was checked by conventional agarose gel
electrophoresis. DNA concentrations were determined by measuring the
absorbance at 260 nm. Finally the template DNA concentration of all samples
was adjusted by dilution in sterile H2O giving an average of 200 ng in each
reaction. Using modern in vitro molecular diagnostic techniques, purified
DNA was analysed to determine the prevalence of a number of selected
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mutations implicated as risk factors in the predisposition of venous
thrombosis.

Prevalence of the Methylenetetrahydrofolate Reductase (MTHFR) C677T
Genotype.

Methylenetetrahydrofolate reductase (MTHFR) is an important enzyme for
folic acid metabolism

Figure 1.7). The enzyme is vital for the reduction

of 5-, 10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, which is the
predominant circulating form of folate. Reduced activity of MTHFR leads to
a accumulation of homocysteine in the bloodstream. A common C to T base
change at nucleotide position 677 in the MTHFR gene produces a
thermolabile form of the enzyme that exhibits approximately 50% of the
normal enzyme activity (Kang et al., 1988; Frosst et al., 1995; Balasa ^ d.,
1999). Hyperhomocysteinemia has been identified as a risk factor for
arteriosclerosis and thrombosis (Rodger et al., 1986; Lentz ^ d., 1991; Adams
et al., 1996; Kluijtmans et d., 1996; Moritaet^., 1997; Margaglione et d.,
1999).
The C to T transition at nucleotide position 677 in the MTHFR gene created a
restriction site for the endonuclease Hinfl. The locus containing this base
change was amplified using suitable primers and PCR to generate a 198 bp
fragment. High quality purified PCR product was subjected to digestion with
Hinfl. When the mutation was present, DNA fragments of 23 and 175 bp,
respectively, were produced following digestion. These were visualised using
conventional agarose gel electrophoresis (see Figure 3.1. lanes 2, 5, 9, 10, 15,
17 and 18 which show undigested DNA fragments and these subjects were
therefore homozygous normal for the MTHFR 677C allele; lanes 3, 6, 8, 11,
12, 13 and 14 showed both 175 bp and 198 bp fragments and were interpreted
as heterozygous for the MTHFR C677T mutation; lanes 4, 7, 16 and 19
showed only the 175 bp band. This was interpreted as homozygous for the
abnormal MTHFR 677T allele). Following RFLP analysis (Figure 3.1), the
prevalence of this mutation in both the Test and Control subjects was
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determined and results are shown in Figure 3.2 (page 82), Tables 3.1 (pages 96
and 97) and Table 3.9 (page 101). In the Test group (n=68) the prevalence of
homozygotes for the mutated allele (C677T) was measured at 8.8% (n=6) with
the prevalence in the Control group measured at 16.2% (n=l 1). In
comparison, the prevalence of the homozygous normal allele was 50% (n=34)
in the Test group and 39.7% (n=27) in the Control group, and for
heterozygotes the prevalence was 41.2% (n=28) in Test subjects and 44.1%
(n=30) in Controls.

These findings show the prevalence of the MTHFR C677T allele in the Test
group to be below that found in the Control group. This difference, however,
between Test and Control genotypes for the MTHFR C677T mutation was not
statistically significant (Chi-squared = 2.34; P=0.05). The incidence of the
mutation in the Test population is not dissimilar to that found in a previously
analysed Caucasian population (see Table 1.5; Vanegas et al., 1998).
Furthermore, the mutation does not appear to be associated with suspected
cancer patients. Additional studies would be required to clearly demonstrate
that the combined effects of the mutation together with other risk factors as
outlined by the THRIFT consensus group (Table 1.1) act synergistically in
increasing the predisposition to thrombosis. In view of the evidence that
suggests the MTHFR C677T allele as a risk factor in thrombosis (Adams ^
al., 1996; Kluijtmans et al., 1996; Margaglione

1999) knowledge of the

patients genotype could be significant in clinical settings. Physicians would
be more vigilant perioperatively for the development of DVT in patients with
this mutation.

It is interesting to note that the higher prevalence of the C677T mutation in the
Control group, (particularly in those homozygous for the abnormal allele)
supports previous findings reporting beneficial effects in individuals
possessing the mutation that may reduce the risk of carcinogenesis (Kamiya et
al., 1998; Pereira et al., 1999).
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Lane:

10 11

12

13

14 15 16 17 18

19 20

198 bp
175 bp

Figure 3.1:

Ethidium bromide-stained 3% (w/v) agarose gel showing PCR
products corresponding to a 198 bp fragment of the MTHFR gene
after digestion with Hinfl restriction enzyme. The C toT substitution
at nucleotide position 677 creates a restriction site for Hinfl that
results in fragments of 23 and 175 bp in length. In the absence of the
mutation, the 198 bp fragment remains undigested. Lanes 1 and 20:
Grade V Molecular Weight Markers (Roche Diagnostics Ltd., East
Sussex, U.K.); Lanes 2, 5, 9, 10, 15, 17 and 18: Homozygous for
normal MTHFR 677C allele; Lanes 3, 6, 8, 11, 12, 13 and 14:
Heterozygous for the mutation; Lanes 4, 7, 16 and 19: Homozygous
for mutated MTHFR 677T allele.

MTHFR C677T genotype distribution among Test and Control
groups
60.0%

50.0%
50.0%
44.1%
■ Test Group

40.0%

□ Control Group

£

I

30.0%

3
3*

b.
20.0%

<

16.2%

10.0%

0.0%

Homozygous Normal

Figure 3.2:

Heterozygous

Homozygous
Abnormal

Comparison of the prevalence of the MTHFR C677T genotype
between Test and Control groups.
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Prevalence of the FXlll Val34Leu Genotype

Blood coagulation factor XIII (FXIII), when activated by thrombin in the
presence of Ca

ions, is an important protransglutaminase involved in cross-

linking fibrin during the final stages of the coagulation cascade (see Figure
1.1). Asa result, thrombi become more stable and less susceptible to the
fibrinolytic reaction. At sites of tissue injury, the local concentration of FXIII
increases due to platelet activation during the haemostatic process. This in
turn may trigger potential pathological thrombotic and thromboembolic
episodes in individuals with increased plasma FXIII concentrations due to the
formation of larger and more stable thrombi (Elbaz et al., 2000; Kohler et al.,
1999). Similarly, interference with the activation site of FXIII leading to more
efficient fibrin cross-linking may also predispose to prothrombotic states.
First described by Mikkola in a Finnish population in 1994, a G to T
transversion in exon 2 of the FXIII A-subunit resulting in the substitution of a
Valine (Val) for a Leucine (Leu) residue has recently been recognised as a
candidate risk factor for thrombosis (Catto et al., 1998 and 1999; Franco et al.,
1999). The proximity of this Val34Leu substitution to the thrombin cleavage
site at 37ArgGly38 is thought to interfere with fibrin cross-linking resulting in
a more efficient FXIII activation (Kohler et al., 1999), the consequence of
which is a prothrombotic state. No direct molecular methods for analysing
this region have been developed to date. Previously SSCP (Orita et al., 1989)
analysis was used to detect base polymorphisms in the candidate region of this
gene. These were characterised by changes in DNA band mobility shifts
under non-denaturing conditions. Base changes were subsequently confirmed
by DNA sequencing. In this study, all purified DNA templates were analysed
by SSCP (for a representative sample ^ Figure 3.3). Any mobility shifts
were further characterised by automated DNA sequencing. Briefly, purified
DNA templates were cloned into pCR® 2.1 using the Original TA Cloning®
Kit (Invitrogen®, Groningen, The Netherlands). Blue-white screening for the
presence of recombinant plasmids was subsequently carried out. Potential
recombinants were initially identified by comparing electrophoretic patterns of
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plasmids purified from blue and white colonies. Plasmids containing inserted
DNA were isolated and purified using the Wizard® Plus SV Minipreps DNA
Purification System kit (Promega, Madison, WI). Presence of the 183 bp
inserted fragment was verified by performing a restriction digest of the
plasmid with EcoRI and subsequent agarose gel electrophoresis analysis for
the appropriately sized fragment. Purified plasmid DNA was subsequently
sequenced using a

2000 DNA Analysis System (Beckman Coulter

Inc., California, USA). A BLAST search (Altschul et al., 1994) of resulting
sequence data against the public database at GenBank was performed to verify
that the fragment sequenced was homologous to human blood coagulation
factor XIII and also to detect the presence of the G to T base change that leads
to the FXIII Val34Leu phenotype.

The results for the SSCP analysis of the FXIII locus in Tests and Controls
were given in Tables 3.1 and 3.2 and are summarised in Table 3.9 and
Figure 3.4. For the homozygous normal FXIII Val allele, the prevalence was
45.6% (n=31) in the Test group and 50% (n=34) in the Control group. In Test
subjects the prevalence of the homozygous mutated allele was 4.4% (n= 3). In
the Control group this value was 3% (n=2). Finally, heterozygosity for the
mutated allele had a prevalence of 50% (n=34) in the Test group and 47%
(n=32) in the Control group.

The prevalence for the FXIII Val34Leu mutation was similar in both the Test
and Control groups. Overall, the prevalence of the mutation was higher in
Test subjects compared to the Control group. This finding was not however
statistically significant (Chi-squared = 0.4; P=0.05). When compared to a
previously analysed Caucasian population (McCormack et al., 1998), there is a
reduced prevalence of the homozygous allele and increased prevalence of the
heterozygous allele in both the Test and Control groups respectively. This
study does not show an association between cancer and possession of the Leu
allele at amino acid position 34 in the A-subunit of factor XIII. As outlined in
Table 3.9, comparison of Tests and Controls on the basis of gender similarly
shows that the prevalence of the mutation was higher in the Test group (males;
57%, n=31; females: 42%, n=6) than in the Control population (males: 54%,
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n=29; females: 36%, n=5). It is important to recognise however, that the
sample population was small and it is acknowledged that a larger sample
group would be more informative of the true prevalence of this genotype.

The precise role of this apparently common polymorphism in the aetiology of
thrombophilia remains unclear. Studies have shown that homozygosity for
FXIII Val34Leu is associated with a significantly decreased risk of venous
thrombosis (Franco ^ al., 1999). In contrast, other data indicated an increased
FXIII transglutaminase activity among carriers of the Val34Leu mutation
(Kangsadalampai and Board, 1998; Kohler et ah, 1998). It would be expected
that the latter higher level of enzyme activity was associated with increased
resistance of the fibrin clot to plasmin degradation. If this feature is
subsequently confirmed, it may be that the FXIII Val34Leu polymorphism
plays a significant role in cancer metastasis by protecting platelet-tumour
thrombi from degradation and prolonging the time in which tumour cells
remain within the vasculature (Dvorak et al., 1981). This may be one possible
consequence of the higher prevalence of the Val34Leu allele in the Test group.
Finally, it may be reasonable to suggest that the FXIII VaI34Leu
polymorphism in the presence of other genetic and/or environmental factors
could, in turn, contribute to the apparent varying role(s) of this polymorphism
in haemostasis.
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Lane:

587 bp
540 bp
504 bp
458 bp
434 bp

267 bp
234 bp
213 bp
192 bp

Figure 3.3:

Silver-stained non-denaturing polyacrylamide gel showing PCR products
corresponding to a 183 bp fragment of the Factor XIII A-subunit gene
following SSCP analysis. Single stranded DNA separates on the basis of
both the size of the fragment and three dimensional conformations that
form under non-denaturing conditions. Hence the apparent larger size of
the fragments. Nucleotide sequence influences the conformation assumed
by single strands and mutations are detected as mobility shift patterns on
the gel. Lanes 1, 2, and 5 through 8: Homozygous for the normal FXIII
Val allele. Lane 3: Homozygous for the abnormal FXIII Val34Leu
allele. Lane 4: Heterozygous for the FXIII Val34Leu allele. Lane 9:
Grade V molecular weight markers (Roche Diagnostics Ltd., East Sussex,
U.K.).
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Factor XIII Val34Leu genotype distribution among Test and
Control groups
60.0%
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Figure 3.4:

Heterozygous
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Comparison of the prevalence of the Factor XIII Val34Leu
genotype between Test and Control groups.
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Novel Factor XIII Leu41 Pro mutation

On the basis of SSCP analysis 37 putative band shifts were identified in
samples obtained from the Test group (Table 3.1) and 34 putative bands shifts
were identified in samples obtained from the Control group. Two of these
were selected, cloned and sequenced by automated methods. An example of
the data obtained from patient T59 is shown in Figure 3.5(a). Comparison
with the normal allele (GenBank Accession number M21987) clearly
identifies the Val34Leu substitution in the latter.

DNA sequence analysis of sample T61, in which a possible mutation in the
FXIII A-subunit was detected by SSCP analysis, revealed a novel
polymorphism close to the thrombin activation site. This mutation involved a
T to C transition 22 bp downstream of the G to T transversion responsible for
the FXIII Val34Leu phenotype (see Figure 3.5 (b)). This new mutation
(Accession Number AF218234) involved a Proline (Pro) amino acid residue
replacing a Leucine (Leu) at position 41,3 amino acid residues on the Cterminal side of the thrombin cleavage site. Furthermore, when the TEG
parameters for this patient were analysed, values showed one of the lowest MA
values of the Test group (45.5 mm). The TEG index was the second lowest of
the entire group at -4.93 indicative of a poor clot tensile strength. The Alpha
angle was also one of the lowest values among the Test group thereby
indicating a slow rate of clot strengthening.

The proximity of this novel polymorphism to the thrombin activation site may
interfere with fibrin cross-linking in a similar fashion to that proposed for the
FXIII Val34 Leu allele thereby predisposing to thrombosis (Kohler et al.,
1998a). This novel mutation could result in defective fibrin cross-linking as
suggested by the TEG results. One possibility is that the mutation caused a
more efficient FXIII activation with subsequent ineffective fibrin
cross-linking. More likely and significantly perhaps is the structural
consequence of a Proline residue replacing Leucine. This amino acid
substitution has significant implications in terms of secondary structure of the
enzyme. Proline is known to destabilise protein secondary structure by
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disrupting K-helices. The physical shape of the FXIII protein could alter close
to the tlirombin cleavage site impairing the action of thrombin. Consequently,
a reduced rate of fibrin cross-linking would (possibly) result.

It is reasonable to suggest that this mutation could prove to be more significant
than the FXIII VaI34Leu allele with respect to thrombotic disorders. The TEG
parameters of sample T66 (see Table 3.1) almost mirror those of patient T6I
and so is a good candidate for possession of the novel mutation. Analysis of
bands on a polyacrylamide gel for subject T66 did not show abnormal SSCP
patterns. This does not entirely rule out the possibility of this novel mutation
being present. The mutation may have presented as homoduplex or
heteroduplex shifts in the gels. These bands migrated faster and were located
further down gels than bands caused by single stranded DNA. Furthermore,
compared to other gene scanning methods of detection (e.g. DGGE), SSCP is
recognised as being 80% effective at detecting base polymorphisms within
DNA fragments of <200 bp (Grompe, 1993).

89

Normal Nucleotide and Amino Acid sequences:
34

35

36

37

39

38

40

41

N
P
V
L
Q
C-Terminal
tN-Tcrminal G
V
V
5'- GGC GTG GTG CCC CGG GGC GTC AAC CTG CAA G1 IGTATGAGC -3'
Intron B
►

Thrombin Activation Site

Nucleotide and Amino Acid sequences containing the Factor XI11 Val34Leu Mutated
Allele Only:
34

35

36

37^ ^

38

39

40

41

L
V
P
R
N
L
N-Terminal
G
G
V
5'- GGC TTG GTG CCC CGG GGC GTC AAC CTG

Q

C-Tcrminal
Intron B-

Fi^ure 3.5 (a):

Comparison of the nucleotide and deduced amino acid sequences in the presence and
absence (GenBank Accession Number M21987) of the FXIIl Val34Leu allele of
exon 2 of the Factor XI11 gene. / denotes end of exon 2

M
T
R
fN-Tcrminal
S^GACCTTGTAAAGTCAAAA (ATG TCA GAA ACT TCCj^GG ACC
5' non-coding region
Exon II
^

AFGGRR
AVPPNNS
GCC TTT GGA GGC AGA AGA GCA GTT CCA CCC AAT AAC TCT

NA
AED
DL
PTV
E
LQ
AAT GCA GCG GAA GAT GAC CTG CCC ACA GTG GAG CTT CAG
Thrombin Activation Site
G

34

35

36

V

V

P

37

38

R \r G

39

40

41

42

V

N

P

Q

GGC GTG GTG CCC CGG GGC GTC AAC ' :cG

C-Tcrminal

<
Intron B

ATACCCCCCTTCCCCACCACTCTGGGT-y
Intron B____________ ^
Figure 3.5 (b):

Nucleotide and deduced amino acid sequences (in red) of exon 2 of the Factor XI11
A-subunit. The 183 bp sequence of test subject ‘T61 ’ shows the thrombin cleavage
site, the putative Val34Leu mutation site (red box) and the location of the novel
Leu41Pro mutation (blue box) at the C-terminal end of the thrombin activation site.
This sequence was submitted to GenBank and assigned the Accession Number
AF218234 (see Appendix 1). Coding region within exon 2 is enclosed in ([) brackets
Notes: fLetters and numbers in red relate to amino acids and their positions
respectively
lAG and GT in hold represent intron-exon junction sites
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Factor V Leiden, Protein C and Antithrombin III analysis
Additional components of the blood clotting pathway (directly or indirectly
involved) were analysed for the presence of mutations. These included
Factor V, Antithrombin III and Protein C. Previously defects in one or other
of these were shown to deregulate the blood clotting mechanism (Dahlback ^
al., 1993; Koster et d., 1993; Lane et al., 1993; Dahlback et al., 1994; Aiachet
1995; Rosendaal et al., 1995; Hillarp ^ al., 1996; Aiach et al., 1997;
Dahlback ^ al., 1997; Kalifatis ^ d., 1997; Rosendaal ^ d., 1997; Murin et
al-, 1998).
Among the 68 Test subjects studied, all were found to be normal for the
Factor V Leiden allele (see Figure 3.6). In addition, none possessed the
relevant mutations in the ATIII and Protein C gene fragments. In view of the
low frequencies of these mutations in the Test group, genotyping the Control
group was suspended.
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Lane:
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540
504
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bp
bp
bp
bp
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234 bp,
213 bp192 bp-

241 bp
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124 bp

Figure 3.6:

Ethidium bromide-stained 2% (w/v) agarose gel showing PCR
products corresponding to a 241 bp fragment of the Factor V gene
after digestion with Hindlll restriction enzyme. Substitution of an A
for a G nucleotide (in Factor V Leiden) creates a restriction site for
Hindlll that results in fragments of 32 and 209 bp in length. In the
absence of the mutation, the 241 bp fragment remains undigested.
Lanes 1 and 6: Grade V Molecular Weight Markers (Roche
Diagnostics Ltd., East Sussex, U.K.). Lane 2: Homozygous for
normal Factor V allele. Lane 3: Heterozygous for Factor V Leiden.
Lane 4: Homozygous for mutated Factor V allele. Lane 5: Lambda
DNA digested with Hindlll (restriction endonuclease control). All
Test subjects were analysed using this method.
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The Functional Assessment of Prothrombotic Tendency

The TEG measures haemostasis by means of an oscillating cuvette and a pin
that is suspended from a torsion wire into the cuvette. For all Test subjects,
freshly drawn whole blood was placed in the cuvette and the real-time blood
clotting characteristics measured. As soon as the first fibrin strands formed
the motion of the oscillating cup was consequently conducted through the pin
to a detector system and the blood clotting trace was displayed over time on a
visual display unit.

In this study, TEG analysis was used to examine whether patient genotype
status for mutations associated with thrombosis was also reflected in the TEG
data. Obviously, it was desirable to analyse both the Test and Control groups
using TEG. However, this was not possible due to the intense demand for use
of this instrument by anaesthetists and other operating theatre personnel.
Hypercoagulability in cancer patients can and has been documented
preoperatively by TEG (Caprini ot ^., 1980; Traverse ^ al., 1993). Since MA
is a measure of tensile clot strength, the results in this study (see Table 3.3)
appear to concur with such empirical and documented evidence since the
average MA value (63 mm) was greater than the normal range for MA
(50-60mm) as given by Mallett et al., 1992. (Unavoidably, this observation
cannot be supported statistically in this case due to the absence of a control set
of results).

The relationships between genotype status for the MTHFR C677T and
Factor XIII Val34Leu alleles and TEG results are outlined in Tables 3.4, 3.5
and 3.6. Most notably the mean Alpha angle (a measure of the speed of clot
strengthening) in patients homozygous for the FXIII Val34Leu allele (44°)
was higher than the average value for the entire group (39°, Table 3.3).
Indeed patient T39 had the highest Alpha angle value (76.5°) among the Test
group. This could reflect the increased transglutaminase activity as a
consequence of the mutation contributing to an enhanced rate of fibrin cross-
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linking (Kohler et al., 1999). In addition, the mean MA was highest in this
group (67 mm. Table 3.5) thereby indicating a more prothrombotic state
compared to the remainder of the Test group (Table 3.3). Perhaps this is
further evidence that the FXIII Val34Leu allele is a genetic risk factor
predisposing to thrombosis. This data illustrated how patient genotype
correlated with a phenotypic trait, in this case features of blood coagulation as
measured using TEG. There are examples however when this hypothesis does
not appear to hold (as in subject T32). This patient was heterozygous for the
FXIII Val34Leu allele yet had one of the lowest r and K values as measured
by TEG. To confirm that these observations (in TEG parameters) are typical
in patients with the FXIII Val34Leu mutation, it would be useful to pursue a
further study involving a greater number of samples. Test patient selection
would be vitally important so as to choose subjects that did not possess any
factors, apart from the FXIII Val34Leu allele, that could potentially contribute
to hypercoagulable features on the TEG.

The TEG parameters for patients homozygous for the MTHFR C677T allele
(Table 3.4) also differed from the overall Test population. Increased r
(40 mm) and X (16 mm) values and decreased MA (58 mm) and Alpha angles
(34°) when compared to the mean values overall, seem to suggest a slower
rate of clot formation with adequate tensile strength.

Test patients that possessed both FXIII Val34Leu and MTHFR C677T
mutations (i.e. compound heterozygotes) displayed mean TEG results that
were not significantly different from the Test group overall (Table 3.6).
Interestingly, one patient that was heterozygous for both of these mutations
(subject T47;

sqq

Table 3.1) had the lowest MA value (41.5 mm) of the study

collection. This patient would have been expected to demonstrate
hypercoagulable characteristics after TEG analysis, given that these mutations
are implicated as thrombotic risk factors. Likewise, the highest MA value of
the study population (89.5 mm) was found in a patient lacking any of the
mutations studied (patient T8; ^ Table 3.1). These data suggest that factors
other than genotypes may play an important role in the development of
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thrombotic states. On this basis, the TEG provides a more relevant “real-time”
analysis of the complete coagulation process. Results of the TEG may
facilitate the mode of pharmacological intervention. Genotype data in contrast
does not necessarily reflect actual “real-time” coagulation characteristics.
Prediction of thrombosis is based only on statistical and empirical associations
with the mutations analysed. Therefore, genotyping may be more useful as a
guide for prophylactic protocols aimed at preventing venous
thromboembolism (Unpublished observation).

95

Table 3.1:

Genotypic and thromboelastographic results of the Test group:

Genotyping Results
Tl
T2
T3
T4
T5
T6
T7
T8
T9
TIO
Til
T12
T13
T14
T15
T16
TI7
T18
T19
T20
T21
T22
T23
T24
T25
T26
T27
T28
T29
T30
T31
T32
T33
T34
T35
T36
T37
T38
T39
T40
T41
T42
T43
T44
T45
T46
T47
T48
T49
T50
T51

Thromboelastography Results

Factor V
Leiden

MTHFR
C677T

FXlll

-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-

+/+
+/+
+/+/-

-/-

j

+/-/-/+/+
+/-/-/+/+/+
-/-/+/+
+/-/+/+/+/+/+/+
+/-/+/-/+/+/-/-/-/+/+/-/+/+/-/-/+/+/+/-/-/-/+/-/+/-/-/-

j

-/-/+/+/+/-/+/-/+/+/-/+/+/+/+/+
-/-/+/-/+/+/+/-/-/+/+/-/+/+/+/-/+/+/+/-/-/+/+/+/+/-/-/-/-/+/-/-/+/+/+

Protein C
-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-

/477//
-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-

(mm)

(mm)

(mm)

Alpha
angle

Lysis
30

Lysis
60

55.5
18.5
38.5
31.5
38.5
29.5
27.0
23.5
56.0
28.0
37.0
26.5
32.0
31.5
25.0
22.0
40.0
18.5
23.5
26.0
36.0
33.5
27.5
35.5
29.5
37.5
30.5
29.0
33.5
31.5
31.5
4.5
43.0
37.0
27.0
20.5
42.0
24.5
38.0
21.0
30.0
34.5
26.5
25.5
23.0
28.0
28.5
43.0
36.5
35.0
27.5

28.0
4.0
27.5
16.0
13.5
15.0
13.5
8.0
23.0
11.0
21.5
14.0
13.0
12.5
12.0
9.5
18.5
8.0
13.0
10.0
11.5
8.5
12.5
11.0
16.5
20.0
8.5
15.0
11.0
9.0
15.0
8.5
19.5
8.5
14.5
3.5
12.0
8.5
4.5
7.0
12.5
11.0
8.0
11.5
9.0
9.0
12.5
14.0
18.0
17.0
8.0

73.5
60.5
48.5
55.5
66.0
55.0
49.0
89.5
50.5
61.5
44.0
42.0
56.0
56.5
59.0
69.5
48.0
65.5
54.0
63.0
55.0
72.5
58.0
60.5
57.5
61.0
74.0
53.5
57.5
74.5
57.0
75.5
57.0
77.0
59.0
87.5
64.5
60.5
61.0
67.5
66.0
63.0
75.0
59.5
72.0
75.5
41.5
84.5
51.5
52.0
69.5

23.0
63.0
15.0
30.5
32.5
28.5
30.0
55.5
19.0
29.5
22.0
31.5
32.0
38.0
35.5
44.5
23.5
46.5
32.5
41.5
37.5
50.0
34.0
36.5
27.5
26.0
48.0
26.0
35.0
52.0
29.5
54.5
24.0
50.0
28.5
73.0
35.5
42.5
76.5
53.0
34.5
39.0
49.0
40.0
50.0
47.0
32.5
39.5
23.5
24.5
45.5

1.0
4.5
0.0
NA
4.0
4.0
11.5
NA
9.0
4.5
6.0
13.5
4.0
1.0
0.0
NA
4.5
2.5
1.5
NA
1.0
9.5
1.5
1.0
1.5
1.5
3.0
1.0
3.0
14.5
1.0
0.0
2.0
0.0
NA
0.5
1.0
1.5
0.5
0.0
1.0
2.0
0.5
1.5
0.5
1.0
2.0
3.0
NA
0.5
0.5

NA
11.5
0.0
NA
4.0
4.0
11.5
NA
9.0
4.5
6.0
13.5
8.5
NA
1.0
NA
10.0
5.5
4.5
NA
4.0
NA
5.5
NA
3.0
NA
6.0
NA
6.5
NA
3.5
1.0
NA
1.5
NA
1.5
2.0
4.0
3.5
1.0
NA
5.5
NA
NA
2.0
2.5
7.0
NA
NA
NA
NA
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TEG
Index
+0.04
+ 1.24
-1.83
-0.29
-0.09
-0.09
-0.82
+5.64
-3.78
+ 1.11
-2.61
-1.95
-0.33
-0.34
+0.93
+2.80
-2.38
+2.50
+0.37
+ 1.31
-1.13
+ 1.74
+0.5
-0.14
+0.36
+0.03
+2.4
-0.21
-0.36
+2.27
-0.03
+5.69
-1.26
+2.05
+0.88
+5.22
-0.25
+ 1.04
-1.39
+2.36
+ 1.50
+0.33
+3.03
+0.84
+2.95
+2.99
-2.32
+2.86
-1.38
-1.14
+2.08

Thromboelastography Results

Genotyping Results
T52
T53
T54
T55
T56
T57
T58
T59
T60
T6l
T62
T63
T64
T65
T66
T67
T68

Factor V
Leiden
-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-

Notes:

MTHFR
C677T
-/-/-/-/-/-/-/+/-/-/+/+/-/-/-/+/+/-

FX/II
-/-/-/+/+/-/+/+/+
-/+/-/-/+/-/+/+/-

Protein C
-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-

/4r/7/
-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-/-

M4
(mm)

(mm)

(mm)

50.0
34.5
35.5
33.0
35.5
31.0
36.5
23.0
40.5
59.5
31.0
NA
45.5
18.5
60.5
35.5
26.5

17.5
7.5
8.0
15.5
9.5
10.5
14.5
5.0
12.0
26.5
5.5
NA
11.0
8.0
23.0
15.0
7.0

74.0
71.0
71.0
52.0
65.0
66.5
61.5
84.5
76.5
45.5
80.0
NA
68.0
67.5
51.5
59.0
73.0

Alpha
angle
34.0
53.5
49.0
27.5
47.0
42.5
30.0
63.0
41.5
16.0
58.5
NA
43.0
49.0
18.5
29.0
54.0

Lysis
30
1.0
1.0
0.5
1.5
2.0
0.0
NA
1.0
0.5
0.5
4.0
NA
51.0
6.5
0.0
0.5
7.0

Lysis
60
3.5
3.5
2.5
5.0
6.0
2.0
NA
4.0
NA
2.0
NA
NA
70.0
13.0
NA
NA
NA

MTHFR = Methylenetetrahydrofolate reductase
FXIIl = Factor XIII Val34Leu '
ATIII = Antithromhin III
-/- = homozygous normal for possession of the relevant allele
+/- = heterozygous for possession of the relevant allele
+/+ = homozygous abnormal for possession of the relevant allele
Compound heterozygotes are indicated by shaded regions
T6I (in blue) are results ofpatient with the 'novel’ FXIII Leu41 Pro
mutation as determined in this project.
Features of the thromboelastographic parameters R, K, MA, Alpha
angle, Lysis 30, Lysis 60, and TEG index are detailed in Section 1.6.
NA = Result not available
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TEG
Index
+0.43
+ 1.28
+ 1.27
-0.99
+0.33
+ 1.25
+0.09
+4.67
+ 1.78
-4.93
+3.06
NA
-0.29
+2.27
-4.16
-0.17
+2.57

Table 3.2: Genotype characteristics of the Control group:

Control Group Genotyping
Results
FXIII Val34Leu
Cl
C2
C3
C4
C5
C6
Cl
C8
C9
CIO
Cll
C12
C13
C14
C15
C16
CIV
C18
C19
C20
C21
C22
C23
C24
C25
C26
C27
C28
C29
C30
C31
C32
C33
C34
C35
C36
C37
C38
C39
C40
C41
C42
C43
C44
C45
C46
C47
C48
C49

+/-/-/-/+/+/+/+
+/-/+/+/-/+/+
-/-/-/-/+/-/-/+/+/-/-/+/-/-/-/-/-/+/-/+/+/+/-/+/-/+/+/+/-/-/-/-/+/-/+/+/-

MTHFR
-/+/+/+
-/+/+/+
+/-/-/+/+/+/+/-/+/+
-/-/+/+
+/+/-/+/+/+
+/+/+/-/-/+/+
+/+/+
-/-/-/+/+/+
+/+
+/+/-/-/-/-/+/+/+/-/+/+
+/+
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Control Group Genotyping
Results
C50
C51
C52
C53
C54
C55
C56
C57
C58
C59
C60
C61
C62
C63
C64
C65
C66
C67
C68

Notes:

FXIII Val34Leu

MTHFR

-/-/+/-/+/-/+/-/-/+/+/+/+/-/+/-/+/+/+/-

+/-/-/+/+/+/+/+/+/-/-/+/+/+/-/-/-/-/-/-

MTHFR = Methylenetetrahydrofolate reductase
FXIII = Factor XIII Val34Leu
-/- = homozygous normal for possession of the relevant allele
+/- = heterozygous for possession of the relevant allele
+/+ = homozygous abnormal for possession of the relevant allele
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Thromboelastography Parameters fn = 68)
K (x ± SD)
MA (x ± SD)
Alpha Angle (x + SD)
13 ±5
63 ± 11
39 ± 13

r(x± SD)
33 ± 10

Table 3.3:

MTHFR
Genotype
-/- (n = 34)
+/- (n =28)
+/+ (n =6)

Table 3.4:

FXllI Val34Leu
Genotype
-/-(n = 31)
+/- (n = 34)
+/+ (n = 3)

Table 3.5:

Mean TEG parameters in the Test group.

Thromboelastography Parameters
K (x ± SD)
MA (x ± SD)

r (x ± SD)
33 ± 11
31 ±5
40 ± 13

13 ±5
12±5
16±8

Table 3.6:

64+ 12
63 ± 10
58 ±8

40+ 14
38 + 12
34 ± 15

Mean TEG parameters in Test group with respect to
MTHFR C677T Genotypes.

Thromboelastography Parameters
K (x ± SD)
MA (x±SD)

r(x± SD)
34 ± 10
31 ± 10
30 ±7

13 ±6
12±5
11 ±6

Alpha Angle (x + SD)

65 ± 10
61 ± 11
67 ± 15

38 + 12
39 + 14
44 ± 16

Mean TEG parameters in Test group with respect to
FXIII Val34Leu genotypes.

r (x ± SD)
Patients with both
FXlll Val34Leu and
MTHFR C677T Mutations
(n= 18)

Alpha Angle (x ± SD)

34 ±7

Thromboelastography Parameters
K (x ± SD)
MA (x ± SD)
13 ±4

Alpha Angle (x + SD)

65± 11

38 ± 11

Mean TEG parameters in Test group patients possessing both
the MTHFR C677T and Factor XIII Val34Leu mutations.
Note:

In all cases above: x = mean; SD = Standard Deviation;
n = number of subjects; Values for r, K, and MA in mm; Value for
Alpha angle in degrees.
-/- = homozygous normal for possession of the relevant allele
+/- = heterozygous for possession of the relevant allele
+/+ = homozygous abnormal for possession of the relevant allele
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Section 4

Conclusions

Conclusions
Modern in vitro molecular diagnostic techniques including Polymerase chain
reaction (PCR), Site-directed mutagenesis (SDM)-PCR, Restriction fragment
length polymorphism (RFLP) analysis, Single stranded conformational
polymorphism (SSCP) analysis and DNA sequencing protocols were used to
analyse 68 Test subjects suspected with cancer and 68 randomised age- and
sex-matched Control subjects (with no history of thrombotic or cancer related
disease) for the following mutations associated with venous thrombosis:
Factor V Leiden (G1691 A)
Methylenetetrahydrofolate Reductase (C677T)
Factor XIII Val34Leu
Protein C TATA variant (A1533G)
Antithrombin III (G13268T)
However, results obtained showed no statistically significant difference
between the Test and Control groups for the prevalence of these mutations.
The molecular protocols used were time-consuming, expensive and
technically difficult to perform. Consequently they are impractical for routine
use. Genotype data may be invaluable in terms of prescribing more
appropriate prophylactic regimens for individuals with acquired increased risk
of thrombosis. Continued research efforts to reduce the time, complexity and
cost of genotype testing is therefore recommended.
Importantly, the higher prevalence of the Factor XIII Val34Leu mutated allele
in subjects suspected with cancer may possibly suggest that this mutation
could play a significant role in cancer metastasis by protecting platelet-tumour
thrombi from degradation.
Thromboelastography (TEG) was used to measure the visco-elastic properties
of whole blood in the Test group. Overall, this group appeared to have a
hypercoagulable state (as expected) on the basis of TEG results. The TEG
was ‘user-friendly’ and provided more relevant “real-time” data regarding
several aspects of the coagulation process that could not be obtained by
genomic analysis. Furthermore, TEG traces often did not reflect
characteristics that would be expected on the basis of genotype analysis and
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strongly suggested that factors other than the associated gene(s) possibly play
significant roles in the coagulation process.
Single stranded conformational analysis and DNA sequencing identified a
novel T->C transition mutation in the gene for the Factor XIII A subunit in
one Test subject (GenBank Accession Number AF218234). At the amino acid
level a proline residue replaced a leucine residue 3 amino acids from the factor
XIII cleavage site. The ability of proline to disrupt protein secondary structure
has major implications in terms of enzyme activity and this was reflected in
TEG results that showed slow clot formation and poor clot tensile strength.
Further studies to identify the significance and consequences of this novel
mutation in a clinical setting would be worthwhile.
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/function="crosslinks fibrin, forming an insoluble
product, at the end stage of the coagulation cascade"
/note="a protransglutaminase glycoprotein activated by
thrombin in the presence of Ca2+; similar to the sequence
deposited in GenBank Accession Number M21987; factor XIII;
http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgj?cmd = Retrieve&db=Nucleotlde&list_uids=76503
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variation

intron

fibrinoligase; plasma transglutaminase"
/codon_start=l
/product="blood coagulation factor XIII a subunit
precursor"
/protein id="AAF65991.1"
/db_xref="GI:7650320"
/translation="MSETSRTAFGGRRAVPPNNSNAAEDDLPTVELQGVVPRGVNPQ"
143
/gene="F13Al"
/replace="t"
149..>183
/gene="F13Al"
/number=B
56 c
47 g
33 t
47 a

BASE COUNT
ORIGIN
1 gaccttgtaa
61 gttccaccca
121 gtggtgcccc
181 ggt

agtcaaaaat gtcagaaact tccaggaccg cctttggagg cagaagagca
ataactctaa tgcagcggaa gatgacctgc ccacagtgga gcttcagggc
ggggcgtcaa cccgcaaggt atgagcatac cccccttccc caccactctg
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